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Abstract

INVESTIGATING SMOKE EXPOSURE AND CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD) WITH A CALIBRATED AGENT BASED MODEL
(ABM) OF IN VITRO FIBROBLAST WOUND HEALING.
By James Alexander Ratti, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Biomedical Engineering at Virginia Commonwealth University.

Virginia Commonwealth University, 2018

Major Director: Rebecca L. Heise
Associate Professor, Biomedical Engineering

COPD is characterized by tissue inflammation and impaired remodeling that
suggests fibroblast maintenance of structural homeostasis is dysregulated. Thus, we
performed in vitro wound healing experiments on normal and diseased human lung
fibroblasts and developed an ABM of fibroblasts closing a scratched monolayer using
NetLogo to evaluate differences due to COPD or cigarette smoke condensate exposure.
This ABM consists of a rule-set governing the healing response, accounting for cell

x

xi
migration, proliferation, death, activation and senescence rates; along with the effects of
heterogeneous activation, phenotypic changes, serum deprivation and exposure to cigarette
smoke condensate or bFGF. Simulations were performed to calibrate parameter-sets for
each cell type using in vitro data of scratch-induced migration, viability, senescenceassociated beta-galactosidase and alpha-smooth muscle actin expression. Parameter
sensitivities around each calibrated parameter-set were analyzed. This model represents the
prototype of a tool designed to explore fibroblast functions in the pathogenesis of COPD
and evaluate potential therapies.

Background
Chronic Obstructive Pulmonary Disease (COPD) & Oxidative Stress
With no cure available and treatments that are only able to manage symptoms –
COPD is currently the third leading cause of death among adults in the United States 1. The
Global Initiative for Chronic Obstructive Lung Disease (GOLD), which provides yearly
updates of recommended methods for the treatment and prevention of COPD, defines it as
“a common, preventable, and treatable disease characterized by persistent respiratory
symptoms and airflow limitation that is due to airway and/or alveolar abnormalities,
usually caused by significant exposure to noxious particles or gases,” such as cigarette
smoke or other pollutants 2,3. This reduction in airflow is due to imbalanced tissue
remodeling that progressively produces both: (A) decreased elastic recoil, small airway
collapse, and loss of alveolar integrity within the parenchyma, along with (B) increased
airway resistance due to narrowed lumen diameters from inflammation, fibrosis and
smooth muscle proliferation within the bronchioles (Figure 1.1) 3–11.
While rare, sometimes heritable, forms of COPD also exist – such as alpha1antitrypsin deficiency disorder which causes tissue degradation through a lack of this
crucial antiprotease 12 – the most common risk factor for COPD is smoking tobacco
followed by exposure to other environmental pollutants and ageing. However, only 25%
of smokers will develop the accelerated decline of respiratory function that is associated
1

2
with clinically significant COPD 13, indicating some genetic risk factors may play a role as
well 2–5,14–16. For this reason, COPD has been classified as a hereditary autoinflammatory
disease, as these are characterized by genetic mutations which produce an overactive or
hyperresponsive innate immune system that typically present with periodic episodes or
flares mediated by interleukin (IL)-1 16.

Figure 1.1 – Mechanisms of airflow limitation in COPD. Reproduced with permission
from 10, copyright Massachusetts Medical Society.

Due to this likelihood that genetic differences exist between smokers who do or do
not develop COPD, specific cell lines have been isolated from human lungs with COPD
(e.g. COPD-Diseased Human Lung Fibroblasts; DHLF) for comparison to genotypicallynormal cell lines from healthy human lungs (e.g. Normal Human Lung Fibroblast; NHLF)
for in vitro research involving COPD 9,17–19. In particular, pulmonary fibroblasts isolated
from people with COPD express increased levels of redox signaling (e.g. isoprostanes,
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elevated NADH/NAD ratio), inflammatory signaling (e.g. PGE2, COX-2, TNFα, TGFβ,
NLRP3-mediated IL-1β, IL-6), myofibroblast markers (e.g. αSMA), senescence markers
(e.g. p16, p21, β-Gal, IL-1α, minimal telomeres), and fail to maintain extracellular matrix
(ECM) homeostasis 3,6,9,16,18–23. Additionally, lung fibroblasts have been shown to
differentially inhibit global protein translation, proliferation, migration, and contraction of
collagen gels within hours 9,21,24,25 – as well as increase senescence over several passages
18,20,26–28

– in response to prostaglandin-E2 (PGE2) in vitro, a common inflammatory

pathway that has been shown to be dysregulated in COPD fibroblasts and directly
correlates with the disease’s severity 9,18,20,24,26.
The proposed inflammatory mechanisms behind COPD’s pathogenesis are a
modified response to respiratory irritants characterized by increased oxidative stress from
activated immune cells, cigarette smoke, and other environmental factors that creates an
amplified inflammatory response, an imbalance of proteases and antiproteases, and an
increase in cellular proliferation, apoptosis and senescence. This is supported by a loss of
alveolar epithelial cells and increased proliferation – evidenced by shortened telomeres
among progenitor and non-senescent cells relative to uninflamed somatic cells – among
samples from patients with COPD. Additionally, increased levels of markers for oxidative
stress (e.g. H2O2, 8-isoprostane), inflammatory cells (e.g. Neutrophils, Macrophages, NKcells), inflammatory mediators, proteases (e.g. MMPs, elastases, cathepsins), and markers
of senescence have been found in samples from patients with COPD 2–6,14,19,29,30 – in fact,
this secretory profile is collectively termed the COPD-associated secretory
phenotype (CASP). While it partially overlaps with some other lung diseases like
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idiopathic pulmonary fibrosis 31, CASP most notably has the same upregulated secretory
profile as the cellular senescence-associated secretory phenotype (SASP) 19. Both secretory
profiles are known to result from oxidative stressors like cigarette smoke and
inflammation, indicating that cell senescence has an active role in COPD pathogenesis
6,18,37–40,19,20,29,32–36.

It is theorized that COPD pathogenesis occurs via chronic oxidative

stress by inducing both apoptosis and senescence – and that senescent cells express a
SASP that is self-promoting, induces senescence in surrounding cells, and progressively
increases the amount of proteases in the extracellular space. Ongoing stimulation by
oxidative stressors can amplify this pathway until the levels of senescent cells becomes
self-sustaining, surpasses the ability of the immune system meant to remove them, and
reduces the tissue’s proliferative capacity to replace lost cells. The resulting imbalances in
cellular apoptosis:proliferation and protease:antiprotease levels are thought to be
independently responsible for driving the degradation of parenchymal tissue at the cellular
and molecular levels, and may explain the observed persistence of inflammation in COPD
patients who quit smoking 6,14,19,29,32.
Likewise, cigarette smoke and oxidative stress have been found to induce
myofibroblast differentiation among lung fibroblasts – both directly and through miR210
containing extracellular vesicles from bronchial epithelial cells 23 – and epithelialmesenchymal transition 41,42, which has been found to be increased in COPD as well 42.
The resulting loss of proliferative epithelial cells paired with an excess of fibroblasts,
myofibroblasts and senescent cells is thought to drive the differential fibrotic and
degradative changes seen in chronic bronchitis and emphysema, respectively.
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Altogether, this review indicates that oxidative stress, PGE2 and NLRP3-mediated
signaling play a major role in the pathogenesis of COPD by promoting inflammation,
mesenchymal differentiation and cellular senescence that subsequently promotes
differential ECM hypertrophy and degradation by tissue type; it’s hoped that mechanisms
which target and suppress these pathways will provide new and effective treatments.
Potentially, multi-scale computational modeling of these pathways – from the molecular
level up to the entire respiratory system – can be used to determine which combination of
these pathways is sufficient to produce the observed clinical symptoms, or if additional
factors (e.g. substrate stiffness, substrate composition, traction forces, cyclical stretch,
metabolic regulation) need to be taken into account within a more complex model.

Pulmonary Wound Healing
Wound healing among embryonic and fetal tissues exhibits full functional
regeneration of injured tissues without scarring, while wound healing of adult tissues often
leads to the formation of scar tissue or fibrosis that can result in a repaired tissue with less
functionality than before the injury 43–46. In non-pathological tissues, adult wound healing
progresses through three overlapping phases: (1) homeostasis and inflammation, (2)
proliferation, construction and remodeling, then (3) resolution 36,44–46. This process occurs
in the lung just as it does throughout the body in general (Figure 1.2).

6

Figure 1.2 – Phases of acute wound healing in the lungs. A damaged section of tissue
experiences an inflammatory response, recovery of lost cell types and ECM components,
and resolution of the healing process as the tissue returns to homeostasis. Reproduced with
permission from 47, copyright the authors.

The initial phase of pulmonary haemostasis and inflammation occurs immediately
following injury – physical trauma activates platelets to induce clotting and stop blood loss
– while trauma, infections, toxins and oxidative stress can all stimulate the release of
inflammatory growth factors and cytokines (e.g. TGFβ, IL-6, PGE2) from platelets,
leukocytes (e.g. neutrophils and macrophages), and damaged resident cells (e.g.
fibroblasts, epithelial cells, endothelial cells) which recruit other cells to the wound site to
amplify this inflammatory signaling and initiate tissue repair. These recruited cells include
additional activated leukocytes to remove dead cells, debris, and invading pathogens from
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the wound; fibroblasts to replace and remodel the damaged ECM; endothelial cells for
angiogenesis within the healing tissue; and other tissue-specific cells necessary for tissue
function – such as bronchial and alveolar epithelial cells in the lungs, keratinocytes in the
skin, or hepatocytes in the liver 36,44–51.
The next phase of pulmonary healing is characterized by the growth of granulation
tissue – named for its granular appearance – through proliferation of these recruited cells to
replace those lost to the injury, construction of new ECM through deposition and
contraction of structural proteins (i.e. collagens and fibronectin), and active angiogenesis to
provide the new tissue with sufficient circulation. Remodeling of the granulation tissue is
effected through continued contraction and cross-linking of newly synthesized ECM by
myofibroblasts, secreted matrix metalloproteases (MMPs), and tissue inhibitors of
metalloproteases (TIMPs); the regulation of these effectors determines the resultant
amount of scarring and fibrosis 11,43–46,48–50.
Resolution of wound healing in the lung is reached when the tissue structure is
restored and excess myofibroblasts and epithelial cells are removed by apoptosis. This
occurs primarily as the newly synthesized ECM is able to take external stress off
myofibroblasts, although increased NO2-signaling or activation of the Fas-apoptotic
pathway by IL-6 sensitized by TNFα can also induce myofibroblast apoptosis. If chronic
inflammation is present, tissue remodeling may persist and cause some cells to become
senescent – from excessive stress, proliferation, or paracrine signaling from other
senescent cells – and thereby target themselves for removal by leukocytes, cease synthesis
of ECM proteins and TGFβ, and gradually upregulate their secretion of MMPs and pro-
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senescence factors (e.g. IL-1α, PGE2, NF-κB, C/EBPβ). Dead or senescent cells cleared
from tissues by the immune system are subsequently replaced through proliferation of
surrounding cells if needed to resolve the chronic healing response. However, prolonged
remodeling by myofibroblasts and senescent cells can cause permanent tissue dysfunction
and preclude a full resolution of wound healing – if either myofibroblasts resist undergoing
apoptosis and senescence, or if the number of senescent cells surpasses the immune
system’s ability to clear them, then tissue remodeling may become progressively and
irreversibly hypertrophic (i.e. stiffer, fibrotic ECM) or degradative (i.e. softer, more
gelatinous ECM), respectively 11,18,39,40,43–46,48–50,52,19,29,32–37.

Fibroblast Heterogeneity & Activation
As the primary mediators of ECM synthesis and remodeling, the main contributors
to tissue repair are resident fibroblasts and myofibroblasts: mechanically-sensitive cells of
mesenchymal origin with a dedifferentiated phenotype. These cells represent a
heterogeneous population, where subpopulations from different locations within the lungs
(i.e. stroma versus parenchymal regions) exist with differing signaling properties 45,48.
They regulate ECM properties through controlled secretion of structural proteins (e.g.
collagen-I, fibronectin, elastin, laminin), proteases, antiproteases, and inflammatory signals
(e.g. TGF-β, IL-6, TNF-α, PGE2, IL-1α) in response to inflammatory stimuli such as
physical trauma, toxins, oxidative stress, or autocrine and paracrine inflammatory signaling
from other fibroblasts, activated leukocytes, epithelial cells and endothelial cells. This
regulation of ECM production and quality of remodeling is achieved via a controlled
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progression of inactivated resident fibroblasts into activated “proto-myofibroblasts” that
may differentiate into myofibroblasts and eventually either apoptose or become senescent
to be targeted for clearance by the immune system 36,38,53–57,43–46,48–51. However, within
COPD these cells express increased levels of inflammatory signals, myofibroblast and
senescence markers, reactive oxidative species (ROS; e.g. OH-, HO2, O2-, H2O2, ONOO-,
etc.), and fail to maintain their native ECM 3,6,24,9,14,18–23.

Figure 1.3 – Fibroblast functions, activation into myofibroblasts and other sources.
Reproduced with permission from 48, copyright the authors.

Inactivated resident lung fibroblasts are found in uninjured tissue and all phases of
wound healing within the intact, cross-linked ECM that stress-shields them and inhibits
their formation of stress fibers or focal adhesions with the ECM. However, once stimulated
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by a change in the mechanical properties of the local ECM that indicates repairs are needed
– for example, provisional ECM (e.g. fibrin clot) stiffness ranges from 10-1000 Pa 49,50,52 –
these cells migrate to the wounded area. These inactive fibroblasts are naturally resistant to
Fas-mediated apoptosis, and will readily proliferate if isolated in vitro; they exhibit
nominal synthesis of ECM proteins (e.g. collagen-I, fibronectin); and form few or no stress
fibers, cell-cell, or cell-ECM interactions – those interactions that do form are often weakly
connected to nascent adhesions (a.k.a. focal complexes) – allowing them to quickly
migrate in response to an injury-induced chemokine or stiffness gradient 11,43,57,45,48–51,53–55.
In the combined presence of transforming growth factor-β (TGFβ) and NADPH
oxidase-4 (NOX4)

39,53–55,

the ED-A slice variant of fibronectin, and a sufficient increase

in mechanical stresses – either of substrate stiffness (≥ ~3 kPa 50), shear stresses from the
edematous increase in extracellular fluid, extracellular stresses from the ECM or adjacent
cells, or intracellular stresses from contraction of the actin cytoskeleton – focal complexes
can form into focal adhesions (FAs; 2-6 μm long 49) capable of supporting stress fibers and
higher traction forces (3-4 nN/μm2 49). These mechanobiological signals spur fibroblasts to
progressively activate into a proto-myofibroblast morphology followed by full
myofibroblast differentiation 45,48,58,59,49–51,53–57. These proto-myofibroblasts are found in all
phases of wound healing from inflammation through remodeling, and will readily
proliferate if cultured in vitro similar to fibroblasts. One activated through force-controlled
release of TGFβ from reservoir proteins bound to the ECM (≥ 5-9 kPa 50), the actin
cytoskeleton is rapidly reorganized to form lamellipodia, numerous focal adhesions, Ncadherin-type cell-cell interactions, and actin stress fibers devoid of alpha-smooth muscle

11
actin (αSMA). Additionally, these proto-myofibroblasts exhibit IL-6 mediated positive
reinforcement of upregulated proliferation, ECM synthesis and contractility, pro-survival
genes, and αSMA expression that’s not yet incorporated into stress fibers 9,43,49–51,53,56,59.

Figure 1.4 – Myofibroblast differentiation mediated by oxidative stress and potential
inhibitors to recover the fibroblast phenotype. Reproduced with permission from 60,
copyright the authors.
With progressive activation of TGFβ and NOX4 signaling along with sufficient
increase in mechanical stimulation – either via substrate stiffness ( ≥ ~20 kPa; thus, most in
vitro cultures of fibroblasts exhibit proto-myofibroblast phenotypes due to tissue culture
plastic’s stiffness in the GPa range 49), shear, extracellular adhesions, or internal
contractility – proto-myofibroblasts may fully differentiate into myofibroblasts as their
focal adhesions coalesce into super-mature focal adhesions (SMFAs; 8-30 μm long, 4-5
fold longer than FAs 49,50) capable of supporting αSMA-containing stress fibers, 3-4 fold
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increased traction stresses (~12 nN/μm2 49), and OB-cadherin (type-11) junctions. While
generally not found in the inflammatory phase of healing, myofibroblasts are primarily
found within the proliferating and remodeling granulation tissue, can originate from
multiple cell types besides resident fibroblasts (e.g. circulating fibrocytes, endothelial cells,
epithelial cells, and smooth muscle cells), and don’t proliferate if isolated in vitro, unlike
inactive fibroblasts and proto-myofibroblasts. The main hallmark of myofibroblasts, their
expression of αSMA-containing stress fibers, is mediated through production via multiple
signaling pathways – including: SMAD2/3, Notch1-Jagged1 (required in vitro), Wnt,
hedgehog, or oxidative stress mediated by NOX4 – and organization into stress fibers
without disrupting the core actin fibril 49,50,61. While myofibroblasts maintain upregulation
of collagen-I and fibronectin, they cease secretion of cytokines. This causes them to
continue synthesizing and contracting new ECM as long as the upregulated TGFβ remains
to provide myofibroblasts resistance to Fas-mediated apoptosis; without protection from
TGFβ, myofibroblasts may apoptose in response to IL-6-and-TNFα or NO2 signaling,
although their strongest stimulus for apoptosis is a loss of external stress indicative of
sufficiently remodeled, structurally sound ECM signaling the end of healing 9,11,50,51,53–
57,36,38,43–46,48,49.

Cellular Senescence: Replicative & Stress-Induced
As part of the tissue’s chronic wound healing response, cellular senescence is
essentially a cellular quarantining mechanism to suspend proliferation and prevent the
spread of any damage to new cells – either until it is able to recover from the stimulus that
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induced it, or until it’s progressively amplified secretory profile attracts a leukocyte to
clear it. Senescence can be induced by shortened telomeres from age or upregulated
proliferation (“replicative senescence”); growth factors (e.g. IL-1β, PGE2), oncogenes, or
stress-induced damage to intracellular components by toxins or oxidative stressors
(“premature senescence” or “stress-induced senescence”); and terminal differentiation
within inappropriate microenvironments (“developmental senescence”). While
developmental senescence earned its name from the controlled senescence and clearance of
excess cell types during development, it is also implicated as a mechanism of senescence
for cells in wound resolution in response to TGFβ. In chronically inflamed wounds,
replicative senescence may be triggered if continual turnover of proliferative cells causes
them to prematurely reach their replicative limit. Likewise, premature stress-induced
senescence may be induced by persistent exposure to oxidative stressors or pro-senescence
growth factors 18,19,62–64,32–37,39,40.
One of the primary mechanisms of chronic lung injury and premature senescence is
from sources such as cigarette and kitchen smoke, or activated leukocytes (i.e. respiratory
burst activity). Excessive reactive oxygen species (ROS; OH -, HO2, O2-, H2O2, ONOO-,
etc.) are known to deactivate antiproteases, damage cells through oxidation of their DNA,
proteins and lipids, and activate inflammatory transcription regulators NF-κB and ERK1/2
3,6,60,65–67,14,18,19,32,33,36,38,39

. If levels of ROS surpass the ability of local antioxidants to

buffer them, then this oxidative stress may either kill cells outright (i.e. cellular necrosis) –
in which case they undergo uncontrolled autolysis, spill their contents into the extracellular
space, and increase the amount of stressors exposed to neighboring cells – or trigger a
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DNA damage response (DDR) that induces growth arrest to begin the cellular repair
process. If a DDR can’t be repaired promptly however, the cell becomes senescent.

Figure 1.5 – Induction of cellular senescence and the SASP. Reproduced with permission
from 63, copyright American Society for Clinical Pharmacology and Therapeutics.

If a cell becomes senescent at any stage, it will increase its resistance to apoptosis,
slow its migration rate, spread out, flatten, and grow up to twice in size 19,33,35,64 –
suggesting an increase in applied traction forces 68,69 – and reorganize its chromatin into
heterochromatin, termed senescence-associated heterochromatic foci (SAHF), thus making
these changed irreversible 33–35,40,62,64. Also, once growth arrest is initiated, senescent cells
begin developing the SASP by expressing IL-1α on their surface to bind adjacent surfacebound receptors. This signaling occurs in autocrine and paracrine fashions to activate the
NF-κB and C/EBPβ transcription factors that mediate full expression of the SASP; this
includes IL-1α, proteases (i.e. MMPs), other cytokines (e.g. IL-6, IL-8) and growth factors
that targets the senescent cells for clearance by the innate immune system (e.g. neutrophils,
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macrophages, NK-cells). Through this process senescent cells will upregulate their
expression of β-Galactosidase (β-Gal), which serves as a useful, although not definitive,
marker for senescent cells 15,18,38–40,62–64,19,20,32–37.

Fibroblast Migration: Individual & Collective
Cellular migration is often represented as a biased random walk such as the Vischek or
Ornstein-Uhlenbeck models 70–72. Individual cells stochastically migrate up gradients of
binding efficiency with the substrate – influenced by gradients of adhesion, topography,
stiffness, chemokines and electrochemistry – which guide the intracellular polarization of
actin polymerization and depolymerization 72–74. In order to do so within two-dimensional
environments, they search for new adhesions through the formation of transient, spatiallystochastic protrusions of filipodia and lamellipodia driven by actin polymerization against
the opposing membrane tension through Cdc42-GTP and Rac1-GTP signaling,
respectively; however, in three dimensions, cells will often form pseudopods or blebs for
more efficient migration in that milieu 75–77. Cells may bind to their substrate through
transmembrane integrin receptors, or with other cells through cadherins, which form
adhesive complexes with the actin cytoskeleton driven by ROCK/MLC mediated RhoAGTP signaling. Myosin-II throughout the actin network, but concentrated near the rear of
the nucleus, then generates tension upon these adhesions in the lamellipodium and ventral
membrane which creates traction and causes the cell body to move forward; in a direction
determined by the balance of adhered protrusions, weighted by their adhesion strength and
stabilized by microtubules. These actomyosin forces also pull the membrane in from the
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back and sides of the cell simultaneously through connections with the cortical actin
network – which induces actin depolymerization and adhesion complex disassembly at the
rear of the cell while generating hydrodynamic flow of the cytosol up to the front of the
cell – to recycle the actin monomers, bundles of myosin-II and associated adhesion
complex proteins needed for continued migration 78–82.

Figure 1.6 – Contact inhibition of locomotion among fibroblasts. Reproduced with
permission from 83, copyright the authors.

The ratio of these cytoskeletal and force-generating protein within each cell determine
the rate of migration, directional persistence, and shape of each cell; those which migrate
faster and with more directional persistence take on a large wide canoe shape with smooth
edges (e.g. keratocytes), while slower wandering cells take on a narrow ‘D’ shape with
unstable edges (e.g. amoebae). Interestingly, cells which take on a canoe shape and migrate
faster with more directional persistence have a higher actin network density – indicating
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we may be able to increase cell migration by upregulating cytoskeletal actin or increasing
actin polymerization with an increase in temperature 84–86.
As a group, fibroblasts fall on the slower, less coordinated side of the spectrum of
migration types described. They’re commonly represented as spindle-shaped, however this
shape is unstable as they lack persistent polarization and exhibit actin fibres oriented at
unexpected angles with respect to the direction of motion 87–90. In barrier removal assays
they show little directional persistence, with an average 2 cell diameters between
independent movements 91. They’re nematic cells which exhibit limited cadherin mediated
cell-cell adhesion with contact-inhibited migration and proliferation; upon division,
daughter fibroblasts disperse 83,87–90,92–95. However, this contact inhibition is not complete
– at confluence in vitro, cryptic lamellipodia extend below neighboring fibroblasts to
migrate through monolayers at approximately a third the rate during pre-confluence 91,96,97
and will keep proliferating albeit at a lower rate 93,94. Yet, if fibroblasts are not yet
confluent and come into contact, they will form transient cell-cell connections which
inhibit further migration and redirect their polarization and resultant migration away from
each other (Figure 1.2), such that the mean velocity of a single cell is inversely
proportional to the amount of cell-cell contacts 83,87–90,92,98,99. This contact inhibition is
reversible (i.e. confluent monolayers can recover prior migration and proliferation rates
when passaged) and mediated by p27(Kip1) induction which also suppresses cellular
senescence by deactivating mTOR; which also explains how cells maintain reversible
quiescence within tissues or confluent monolayers 100,101.
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As a result of this contact inhibition, jamming of fibroblast monolayers as cell densities
increase have been modeled as liquid crystals 102, and barrier removal experiments have
been performed in vitro to evaluate the release of contact inhibition on their migration
70,71,103.

Barrier removal experiments are preferred over scratch assays for the study of

collective migration since the former method limits damage to cells, is more reproducible,
and allows various monolayer geometries to be formed that allow for the evaluation of
changes due to the orientation of individuals or level of orientation-order among the
population. However, the cell damage produced by scratch assays is preferable to mimic
wound healing despite the decreased reproducibility of these experiments. Thus, to model
wound healing within the lung in vitro, we opted for a scratch closure assay.

Agent Based Models
To model our scratch closure assays in silico, we opted for an ABM to study how
the dynamics of fibroblast activation and senescence affect their collective migration to
evaluate changes due to treatments or exposures with computational efficiency. While
comprehensive models taking a systems-biology approach to model fibroblast wound
healing have also been formulated 104–106, these are computationally intensive. Many other
types of stochastic active particle models are also well-suited for studying wound healing
and collective cell migration, however these are all physics-based models that study how
the dynamics of cell-substrate and cell-cell connections between particles generate
phenomena such as actin polarity emergence 107, monolayer jamming 70,95,102, flocking
70,108

, digitation features among epithelial sheets 71,109, angiogenesis 110, or collagen
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deposition and contraction 111. Fortunately, efforts to model inflammatory responses
utilizing multiple cell states (e.g. damaged and healthy) and cell types (e.g. epithelial and
immune) have exemplified the value of ABM techniques 112–116. An ABM produced by
Brown et al 113 even produced a model smoke particulate exposure on fibroblast
maintenance of the ECM and macrophage-mediated inflammation that managed to
approximate fibrotic features observed within mouse models of smoke exposure. However,
this model was limited in its ability to account for the direct effects of smoke exposure on
their myofibroblast activation or senescence.
In contrast with ordinary and partial differential equations that model pooled
population dynamics in a top-down manner, ABMs represent a bottom-up approach that
excel at modeling emergent collective behaviors due to interactions between individuals
and their environment. Agents are mobile individuals interacting with an immobile lattice
of patches according to a set of rules. Agents often represent cells while patches represent
the substrate or sheet of epithelial cells. Models may incorporate multiple types of agent or
patch with their own subset of rules, multiple layers in two dimensions, or three
dimensions. To facilitate these models, several modeling platforms have been developed
114,115,117,118.

While slower than other platforms, NetLogo 119 is open-source, easy to use

and has several built-in tools such as BehaviorSpace to assist with model analysis 114,115,118.
Some ABMs also include continuum mechanic modules to create a hybrid model 120.
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Here, we model the collective migration dynamics of fibroblasts closing a
scratched monolayer influenced by the differential stimulation of myofibroblast activation
and senescence produced from a distribution of sensitivities to a constant environmental
stimulus. This model is designed to evaluate differences between fibroblast populations to
which the model is calibrated with in vitro data by representing their response as a set of
parameters governing basal rates of migration, proliferation, senescence and myofibroblast
differentiation.

Project Objectives
1. In Vitro: Quantify the in vitro scratch wound closure along with the percentage of
cell death, cell senescence and myofibroblasts among human lung fibroblasts.
2. In Silico: Using NetLogo, develop an ABM of fibroblast wound healing to evaluate
differences among parameter-sets calibrated to in vitro data from Objective 1.

In Vitro Methods
Cell Culture & Treatment Medias
Normal Human Lung Fibroblasts (NHLF; CC-2512), and Diseased Human Lung
Fibroblasts (DHLF; 195277) derived from COPD patients, were obtained from Lonza for
all in vitro studies. NHLF and DHLF were only used for passages 5-9 and 2-3,
respectively. Cells were expanded and cultured in Fibroblast Growth Media-2 (FGM; CC3132, Lonza) that was refreshed every 2-3 days. When 80-90% confluent, cells were
dissociated with 0.025% Trypsin/EDTA and passaged with a 1:7 split.
Cigarette Smoke Condensate (CSC) was obtained from Murty Pharmaceuticals
(Lexington, KY) and diluted to a 0.125% (50 mg/ml) solution with Fibroblast Basal
Medium (FBM; CC-3131, Lonza). According to the manufacturer, the CSC stock was
prepared from smoking University of Kentucky’s 3R4F Standard Research Cigarettes on
an FTC Smoke Machine; total particulate matter on the filter was calculated from its
weight gain, then DMSO was used to extract the condensate via soaking and sonication to
produce an approximate 40 mg/ml solution. This stock was subsequently diluted in FBM
and sterile-filtered (0.22 um pore size) to make the CSC treatments. DMSO diluted in
FBM was used as a vehicle control.
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Metabolic Assays
To assess the toxicity of CSC dilutions, evaluate the effect contribution of the
dimethylsulfoxide (DMSO) vehicle and compare the metabolic effects of the treatment
medias, cells were seeded into flat-bottomed 96-well plates (Corning) at a density of 62500
cells/cm2 with 200 μl FGM. After 14 hours of growth, the seeding media was aspirated and
replaced with 100 μl of the treatment medias. Following 0, 0.5, 2, 12, or 24 hours of
treatment, media was replaced with 100 µl FBM plus 10 µl of either MTT (#11465007001,
Sigma) or CCK-8 (Dojindo) reagent.
For MTT assays, cells were incubated with the MTT reagent for 4 hours, then 100
µl of the MTT Solubilization Solution was added and further incubated overnight to
solubilize the MTT formazan reduction product. The optical density (OD) of formazan was
then measured at 570 nm using a BioTek Epoch Spectrophotometer; background
absorbance was also measured at 650 nm, and the difference between these optical
densities (i.e. OD570 – OD650) was calculated to represent the amount of MTT formazan
resulting from reductive metabolic processes.
For CCK-8 assays, cells were incubated with the WST-8 reagent for 4 hours, then
the media was aspirated and replaced with 100 µl DMSO to solubilize the WST-8
formazan reduction product over 10-15 minutes at room temperature. The optical density
of WST-8 formazan was then measured at 450 nm; background absorbance was also
measured at 600 nm, and the difference between these (i.e. OD 450 – OD600) was calculated
to represent the concentration of WST-8 formazan resulting from reductive metabolic
processes.
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Scratch Wound Healing Assays
Wound healing was evaluated by proxy through the in vitro assessment of
collective fibroblast migration within scratched monolayers. Cells were seeded with 2 ml
of FGM at a density of 42100 cells/cm2 (~400,000 cells/well) into clear tissue culture
treated 6-well plates (Corning), after horizontal marks were drawn through the center of
each well along the underside of the plate. After incubation for 14 hours, each cell
monolayer was scratched vertically with a 20 μm pipette tip, rinsed with 30 mM HEPES
Buffered Saline, and then covered with 2 ml of the treatment media. Each monolayer was
imaged immediately after the scratch and at each time-point (i.e. a series of {0, 4, 8, 12,
24} or {0, 12, 16, 20, 24} hours) in two locations, one above the horizontal mark and the
other below, on an Olympus IX71 Microscope under phase contrast with QCapture Pro 6.0
software. The same locations were imaged across successive time-points through the use of
a reference point (i.e. a trivial portion of the horizontal mark visible through the bottom of
the plate); however if this default reference was not usable (e.g. the scratch retracted near
the mark in the center of the well, but not elsewhere), then filenames were notated and
alternate features (e.g. whorl patterns distant from the scratch, scratches in the plastic, etc.)
were utilized as substitute references. The denuded area was measured in triplicate using
the freehand selections tool within ImageJ 121,122, and subsequently expressed as the
percentage of scratch closure (%𝐻𝑒𝑎𝑙𝑖𝑛𝑔 = (𝐴𝑟𝑒𝑎𝑖𝑛𝑖𝑡𝑖𝑎𝑙 – 𝐴𝑟𝑒𝑎𝑐𝑢𝑟𝑟𝑒𝑛𝑡 ) / 𝐴𝑟𝑒𝑎𝑖𝑛𝑖𝑡𝑖𝑎𝑙 )).
Measurements from technical repeats (i.e. triplicate measurements of duplicate images of
triplicate wells) within each experimental group were averaged together to form a single
biological repeat for statistical comparisons.
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Cytometric Stain Assays
For all staining experiments, cells were seeded with 2 ml of FGM at a density of
42100 cells/cm2 (~80,000 cells/well) into clear tissue culture treated 24-well plates
(Corning), then fixed and/or stained after 6, 14, 26, or 38 hours of incubation after seeding.
To evaluate population changes within the context of our scratch assay model, each cell
monolayer was scratched with a 20 μl pipette tip, rinsed with 30 mM HEPES Buffered
Saline, and then covered with 400 μl of the treatment media after 14 hours of growth. To
capture population changes caused by the scratch and wash step, separate experiments
were collected at 14 hours either with or without scratched monolayers. After staining, all
plates were viewed and imaged on an Olympus IX71 Microscope equipped with QCapture
Pro 6.0 software. Each well was imaged in three locations – with two centered on the
scratch, if present, and one distant from it – and each location was imaged using two
channels in order to determine the relative size of the targeted subpopulation of cells (i.e.
dead, senescent or myofibroblast) among the whole population in each image. The total
cell populations determined from each type of staining assay were pooled for each
experimental group to determine total population changes with time.
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Viability Stain
Cell death was evaluated using a fluorescent viability staining kit (L3224,
Invitrogen). Briefly, media was aspirated, 200 µl of the staining solution containing 2 µM
calcein AM (live; FITC, ~450-500 nm) and 4 µM EthD-1 (dead; TRITC, ~500-550 nm)
was applied and incubated at room temperature for 30 minutes. Cells were then imaged
using a QImaging EXi Blue fluorescence microscopy camera with FITC and TRITC
channels. The total cell population was calculated as the sum of all live and dead cells, thus
the percentage of dead cells was calculated as = 100 ∗ (𝑁𝑑𝑒𝑎𝑑 / (𝑁𝑙𝑖𝑣𝑒 + 𝑁𝑑𝑒𝑎𝑑 )).

Senescence Associated Beta-Galactosidase (SA-β-Gal) Stain
To determine the proportion of senescent cells within the fibroblast monolayers,
cells were first stained with the SA-β-Gal staining kit (#9860, Cell Signaling
Technologies) according to the manufacturer’s protocol, then rinsed twice with PBS and
counterstained and cured overnight at room temperature using ProLong® Gold Antifade
Mountant with DAPI (P36931, ThermoFisher). Cells were then imaged using a QImaging
MicroPublisher 3.3 RTV camera with channels for brightfield illumination and DAPI
(~330-380 nm). The number of blue-stained cells under brightfield illumination were
considered positive for senescence (if selected by ImageJ thresholds) and the number of
DAPI-stained particles (i.e. nuclei) was used to represent the total cell population, thus the
percentage of dead cells was calculated as = 100 ∗ (𝑁𝑆𝐴.𝛽.𝐺𝑎𝑙 /𝑁𝐷𝐴𝑃𝐼 ).
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Alpha-Smooth Muscle Actin (αSMA) Immunocytochemistry Stain
To determine the proportion of myofibroblasts within the fibroblast monolayers,
cells were first washed twice with PBS, fixed with 200 µl of 4% paraformaldehyde for
20min at room temp, then washed twice again with PBS. Cells were permeabilized with
0.1% v/v Triton-X100/PBS for 10 minutes, washed four times with 0.1% Tween-20/PBS
(PBST) for 5min each, then blocked with 200 µl of 5% Bovine Serum Albumin/PBST
(BSA/PBST) for 1 hour at room temperature. Blocked cells were incubated with 200 µl of
a 1:400 dilution of anti-αSMA monoclonal mouse antibodies (#A2547, Sigma) within
BSA/PBST overnight at 4°C. Primary antibody-tagged cells were washed thrice with PBS
for 5min each then incubated with 200 µl of a 1:2000 dilution of anti-mouse IgG (H+L)
polyclonal goat antibodies conjugated with Alexa Flour 488 fluorophores (#A-11001,
ThermoFisher) for 2 hours in the dark at room temperature. Secondary antibody-stained
cells were rinsed thrice with PBS for 5 minutes each, counterstained and cured overnight
with ProLong® Gold Antifade Mountant with DAPI (P36931, ThermoFisher), then imaged
using a QImaging EXi Blue fluorescence microscopy camera with FITC and DAPI
channels. All DAPI-stained particles that colocalized within stained regions of αSMA
fibers determined with the ImageJ plugin JACoP 123 were considered positively-tagged
myofibroblasts, while the total number of DAPI-stained particles was used to represent the
total cell population, thus the percentage of myofibroblasts was calculated as
= 100 ∗ (𝑁𝑐𝑜𝑙𝑜𝑐𝑎𝑙(𝐷𝐴𝑃𝐼+𝑎𝑆𝑀𝐴) / 𝑁𝐷𝐴𝑃𝐼 ).
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Statistical Analyses
Scratch assays were analyzed using two-way ANOVAs with repeated measures and
Holm-Sidak post-hoc tests for multiple comparisons to evaluate differences among paired
time-points between cell lines (i.e. NHLF vs DHLF) and treatment medias (i.e. FBM,
FGM and 50 µg/ml CSC) across groups within time-points or within groups across time.
Scratch assay analyses were performed for an overall view (i.e. 0, 12 and 24 hours).
MTT and CCK-8 assays were analyzed using two-way ANOVAs with Holm-Sidak
post-hoc tests for multiple comparisons to evaluate differences between treatment medias
(i.e. FBM, FGM, and titrations of CSC or DMSO) and unpaired time-points.
Staining assays (i.e. SA-β-Gal, Viability, and ɑSMA) were also analyzed using
two-way ANOVAs with Holm-Sidak post-hoc tests for multiple comparisons to evaluate
differences between treatment medias (i.e. FBM, FGM and 0.125% CSC) and unpaired
time-points.
All data were collected and pre-processed within Excel; all statistics were
performed within GraphPad Prism 6 software. Differences with p-values < 0.05 were
considered significant. Unless otherwise noted, all experiments were performed with a
minimum of N = 3 biological repeats in triplicate.
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In Silico Methods
Fundamentally, this agent based model is designed to simulate fibroblasts within
the context of an in vitro scratch wound healing assay in order to characterize their timedependent response in terms of the population’s proportions of inactive, active,
myofibroblast and senescent states along with their mean rates of migration, proliferation
and death. The model operates on NetLogo version 5.3.1. The in vitro environment is
represented by a two dimensional lattice network of square patch units, fibroblasts are
represented by mobile agents, and the model rules are applied each tick to represent their
activity in 20 minute steps. Agents interact with other nearby agents and the Moore’s
neighborhood of patches below them, consisting of the central patch beneath the agent’s
center and the eight surrounding patches, through a series of rules and procedures designed
to model the scratch closure behavior of fibroblasts in vitro. Simulations to find calibrated
parameter-sets for the in vitro datasets and analyze parameter sensitivities were performed
using the BehaviorSpace tool with 10 simulation runs per parameter-set evaluated.

Model Setup
The model world consists of 101x101 patch units representing the 2.8123 mm2 area
evaluated in the in vitro scratch assays. Each patch (XY) has a unit length equivalent to
16.6040 μm. This lattice has a periodic boundary, so a fibroblast agent moving beyond one
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edge is reintroduced at the opposite edge. While they are displayed with various shapes,
each of the N fibroblast agents is modeled as a circle and assigned attributes associated
with one of the following states that a fibroblast may exhibit in vitro: 1) Inactivated
Fibroblasts (IFibs) represent immobile, inactive fibroblasts that have not yet been activated
by the tissue culture plastic beneath them; 2) Activated Fibroblasts (AFibs) represent
mobile, αSMA-negative fibroblasts (i.e. proto-myofibroblasts); 3) Myofibroblasts (MFibs)
represent mobile, αSMA-expressing fibroblasts; 4) Senescent Fibroblasts (SFibs) represent
non-proliferating, apoptosis-resistant fibroblasts that have lost their contact inhibition; and
dead cells (DFibs) interact with nothing. Each of these agent states (F) has a defined size
(S(F)), migration rate (M(F)), resistance to apoptosis (R(F)), and proliferation rate (D(F,N)).
Each agent also has their own rate of senescence due to replication based on the Hayflick
limit (TSENESCE(F,N)), sensitivity to stimulatory signaling (Z(N)), level of stimulation (stim(N)),
and set of stimulation-dependent transition probabilities governing changes between agent
states. All fibroblasts are capable of dying or becoming senescent due to stimulation;
however IFibs can also activate into AFibs, and AFibs can also deactivate back into IFibs
or become MFibs through further activation signaling. The model parameters for mean
migration rate (M0) and mean division interval (TDIVIDE) are attributed to active fibroblasts
and used as baselines for the other states. More details on these attributes and other
variables – including values, calculations and citations – are available in Appendix B.
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Initial Conditions & Agent Preconditioning
Fibroblast agents are generated at random locations within the model world with
the same percentages of senescent cells, myofibroblasts, and dead cells as were measured
in vitro among NHLF in FGM incubated for 6 hours post-seeding, when cells first attached
to and flattened out on the plate (data not shown). All remaining agents are generated as
AFibs to model the in vitro activation response of fibroblasts attached to tissue culture
plastic (TCP). As shown in the top row of Figure 3.1, the agents are capable of
deactivating into IFibs within the model, however the stimulation threshold which controls
this state transition is set at such a low level that AFibs do not deactivate beyond the first
few steps to mimic fibroblasts becoming fully attached to and stimulated by the nonphysiologic stiffness of the tissue culture plastic to which they’re attached after 6-8 hours
in culture. These initial agents are generated with a population (Pop_t00) equal to the
seeding density used in vitro (Pop_t00 = 400,000 cells/well = 416.67 cells/mm2). The
precondition procedure runs the model a number of steps equivalent to the in vitro time
interval between the seeding and the scratching of wells during a scratch assay
(Time_seed-scratch = 8 hours) using the parameter-set calibrated to in vitro data for NHLF
treated with FGM (Table 4.1). This step is necessary to initialize their spatial distribution,
stimulation levels stim(N), division counters D(F,N), and replicative senescence counters
TSENESCE(F,N). At the end of the precondition step, parameter values are switched to the
parameter-set associated with the scratch closure response, and the associated agent
variables governing stimulation sensitivity (Z(N)) and division interval (D(F,N)) are averaged
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together to represent an agent’s memory of past exposures and prevent artifact shifts in the
agent states.

Scratch Implementation & Closure Measurement
To model the scratch, all agents within the defined Scratch Region are removed to
simulate a monolayer of fibroblasts being scratched in vitro. Dead agents are also removed
regardless of their location to simulate the in vitro post-scratch wash step, adjusted such
that 8.05% of the resulting agent population consists of DFibs to mimic the percentage of
dead cells found in vitro 0 hours after the scratch. The Scratch Region extends vertically
down the model world, centered on the y-axis, and its ratio of patches within the model
world is equivalent to the in vitro ratio of scratched to non-scratched areas within a squarecropped image centered on the scratch. This is shown in the bottom row of Figure 3.1.
Every patch possesses two variables accounting for the relative coverage of
neighboring patches by agents, termed “Void Scores,” that are used to measure the current
cell coverage of the Scratch Region (Healed Region) and model the in vitro contact
inhibition of migrating and proliferating fibroblasts (i.e. Rules #1 & #2 detailed below;
also illustrated in Figure 3.2). Each time step, each patch (XY) calculates the Primary Void
Score (V1(XY)) as the averaged count of patches within its Moore neighborhood, e.g. the
bold-edged patches in Figure 3.2), not including itself, that are devoid of any live fibroblast
agents. Then the model calculates a Secondary Void Score (V2(XY)) as the average V1(XY) of
the same neighboring patches. Any patch within the Scratch Region with a V1(XY) or V2(XY)
less than 0.5 is considered to contain a fibroblast and is included as part of the Healed
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Region (e.g. the green-filled patches in Figure 3.2).The percentage of the scratch region
which is also part of the healed region (%Healed) is used as an output parameter for
comparison to percentage healed data from in vitro scratch assays.

T = seed

T = seed + 1

T = pre-scratch

T = scratch + 0

T = scratch + 12

T = scratch + 24

Figure 3.1 – Representative simulation of fibroblast agents closing a scratch. Time-points
are shown during the pre-scratch and post-scratch intervals when agents are initially seeded
(top left), one step after seeding (top middle), immediately prior to being scratched after 8
hours of growth (top right), and after being scratched for 0, 12 or 24 simulated hours
(bottom row). Unscratched patches are colored black, Scratched patches are grey, Healed
patches are lime green, and Unhealed Edge patches are light grey. IFibs are displayed as
yellow triangles, AFibs as teal squares, MFibs as green clovers, and SFibs as dark green
circles. All agents are modeled to scale as circles but not displayed as such.
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The length of the border between the Healed Region and the rest of the Scratch
Region, relative to its length when the scratch was created (Relative Unhealed Edge
Length), is used to quantify the amount of disorder in the fibroblasts’ invasion of the
scratch region. The relative unhealed edge length is also used as an output parameter for
comparison to relative scratch edge length data from in vitro scratch assays; however this
was not used to calibrate parameter-sets of the model.

Figure 3.2 – Patch diagram displaying how Void Scores are calculated and used. This
method measures the Healed Region and guides the navigation of circular fibroblast agents
as described in Rule #1. The bold-outlined patches represent the Moore’s neighborhood for
the fibroblast agent in the center; the whole number within each patch is the patch’s V1(XY)
score while the value in parenthesis is its V2(XY) score.
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Model Rules
The dynamics of fibroblast migration, proliferation, senescence, myofibroblast
activation and death within the model presented are controlled by the following rules.
These are implemented each time step to generate scratch closure as seen in Figure 3.1.

Rule #1a: A non-senescent fibroblast having any neighboring patches with a V2(XY) above
0.5 will migrate M(F) distance towards the neighboring patch with the greatest V2(XY) with a
standard deviation of 15°.

This mechanism of agent navigation is intended to mimic the migratory contact
inhibition exhibited by non-senescent fibroblasts in vitro, whereby those which come into
contact tend to migrate away from each other 87–90. In contrast, senescent fibroblasts have
been reported to lose this contact inhibition 63,124. Directional migration is reported to be
dependent upon phosphorylation of calveolin-1 to inhibit Rho signaling and increase
activity of Rac1 and Cdc42 to reorient the actomyosin machinery polarization 125.
Additionally, caveolin-1 is required for α5β1-integrin endocytosis crucial for migration 126.
Since senescent cells exhibit upregulated caveolin-1 along with high activation of Rac1
and Cdc42 127–129, that’s reversible along with the senescent phenotype when Caveolin-1
status is decreased 129, we model senescent cell migration with a random walk.

Rule #1b: A senescent fibroblast migrates M(S) distance in a random direction, regardless
of its patch neighbors’ Void Scores.
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Rule #2a: A non-senescent fibroblast may divide after growing for D(F,N) hours, if and only
if a patch in the Moore neighborhood of the patch beneath it has a V2(XY) score above 0.5.
D(F,N) is randomly generated for each agent when it is introduced to the model world and
each time it divides from a normal distribution with a mean of TDIVIDE, adjusted for each
agent state F (see Figure 3.3), with a standard deviation of one third this value.

Rule#2b: Senescent cells do not divide. This is the definition of senescence 35,40,64,130,131.

Both daughter cells inherit the parent cell’s stim (N) level to model the even splitting
of cellular contents between daughter cells that conserves the parent cell’s proportions of
receptors to ligands. Daughter cells also maintain the parent cell’s activity state and
TSENESCE counter value (see Rule #3) to model the conservation of their parent cell’s
expression profile and division history (i.e. telomere length), respectively. One daughter
cell remains on the patch below the parent cell, while the other moves into the patch with
the greatest V2(XY) in its neighborhood. This method of cell division is intended to model
the contact inhibition of proliferation among cells in vitro – whereby a population’s rate of
division decreases in proportion to increasing population density 93,94,100,132 and “new” cells
are preferentially added within the plane of the monolayer, rather than atop or beneath the
“parent” cells 103. All agents have their D(F,N) value reassigned at the time of the scratch
and averaged with its pre-scratch value to model a cell’s memory of previous exposures
within a two-hit exposure system.
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Rule #3: A non-senescent fibroblast becomes senescent after TSENESCE time steps, where
TSENESCE is stochastically assigned to agents during model initialization from a normal
distribution with a mean of 40 * D(F) and a standard deviation of 40 * TDIVIDE / 3. This
counter models the replication induced senescence reported to occur in all cells after 50±10
population doublings, known as the Hayflick limit 63,124; however we limited agents to 40
divisions to account for presumably shorter telomeres among our cells, derived from an
adult population, versus the embryological cells used by Hayflick.

Figure 3.3 – Flow diagram of fibroblast agent states, characteristics and associated rules.
Each fibroblast phenotype (F) has characteristic values describing each state’s size (S(F)),
migration rate (M(F)), mean division interval (D(F)), and death resistance (R(F)). The
corresponding rate or probability regarding proliferation (Rule #2; black), replicative
senescence (Rule #3; purple), cell death (Rule #5; blue) and stimulation-induced state
transitions (Rules #6-9; green-red gradient) are described in the text; color-legend
regarding Rules #5-9 correlate with Figure 3.4.
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Rule #4: Each time step, every agent increases their internal level of stimulation, stim(N),
by the product of their sensitivity to stimulation (Z(N)) and the magnitude of environmental
stimuli (μSTIM). Agents are assigned a sensitivity to stimulation Z(N) from a normal
distribution with a mean of 1 and standard deviation of σSTIM, and this Z(N) value is
preserved among daughter cells when a fibroblast divides. All agents have their Z(N) value
reassigned at the time of the scratch and averaged with its pre-scratch value to model a
cell’s memory of previous exposures within a two-hit exposure system. The stim(N) level
for each fibroblast represents the sum of activity among all intracellular signaling pathways
that can induce activation, senescence, or apoptosis (e.g. NOX4, SMADs, p21, p16, p53,
etc.). The μSTIM parameter represents the magnitude of the sum of all stimuli within the in
vitro environment that can induce fibroblast activation and senescence (e.g. substrate
stiffness, CSC, ROS, FGFβ, TGFβ, PGE2); whereas the σSTIM parameter represents the
variation in sensitivity to these stimuli among individual cells in a population to model a
heterogeneous response to stimuli among the cell population and prevent all of the agents
from transitioning simultaneously.
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Figure 3.4 – Plot of the probabilities governing agent transitions between states. Each
agent’s transition probabilities (colored lines) depend upon their stim(N) and the
population’s transition thresholds (horizontal black bars); representing the mean values
associated with a 50% probability for each state transition (L(F); black bars). Fibroblasts
continually increase their stim(N) (Rule#4), which directly and linearly increase their
probability for each state transition (Rules #5-9). Both L(M) and L(S) (bars with arrows)
serve as parameters that directly control the transition probabilities and subpopulations of
myofibroblasts and senescent cells, respectively. Color-codes for each transition
probability are consistent with Figure 3.3.

Rule #5: Each time step, all living agents have a P D(F,N) probability of death due to stimuli,
such that:
𝑃𝐷(𝐹,𝑁) =

𝑠𝑡𝑖𝑚(𝑁)
2𝐿𝐷 𝑅(𝐹)

where R(F) represents the resistance to apoptosis for each fibroblast state or phenotype, F.
The damage level at which a fibroblast is 50% likely to die (LD) is arbitrarily set to 1 stim
in order to give the stimulation parameters a reference value. The line associated with this
probability is plotted in Figure 3.4 in yellow.
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Rule #6: Each time step, all inactive agents have a PA(N) probability of activation, such
that:
𝑃𝐴(𝑁) =

𝑠𝑡𝑖𝑚(𝑁)
2𝐿𝐴

Rule #7: Each time step, all active agents have a P-A(N) probability of deactivation, such
that:
𝑃−𝐴(𝑁) =

2𝐿𝐴 − 𝑠𝑡𝑖𝑚(𝑁)
𝑠𝑡𝑖𝑚(𝑁)
=1−
2𝐿−𝐴
2𝐿𝐴

The stimulation limits for governing an agent’s transition to an activated or
inactivated state, LA or L-A, respectively, are set equal to each other in order to allow an
AFib the chance to transition back into an IFib if their stim(N) level is low enough. These
shared stimulation limits for activation represent the average stim(N) level at which
fibroblasts are 50% likely to be inactivated or activated. This functionality is designed to
model fibroblasts’ tendency to remain inactivated in the absence of stimuli along with their
ability to deactivate once activated if their internal level of stimulation is resolved.

Rule #8: Each time step, all active agents have a PM(N) probability of becoming
myofibroblasts, such that:
𝑃𝑀(𝑁) =

𝑠𝑡𝑖𝑚(𝑁) − 𝐿𝐴
2(𝐿𝑀 − 𝐿𝐴 )
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where the model parameter LM is the stim limit representing the average stim(N) level at
which an activated fibroblast is 50% likely to become an αSMA-expressing myofibroblast.

Rule #9: Each time step, all active agents have a PS(N) probability of becoming senescent
due to stimuli, such that:
𝑃𝑆(𝑁) =

𝑠𝑡𝑖𝑚(𝑁) − 𝐿𝐴
2(𝐿𝑆 − 𝐿𝐴 )

where the model parameter LS is the stim limit representing the average stim(N) level at
which an activated fibroblast or myofibroblast is 50% likely to become senescent.

The effect of these LF given in Rules #5-9 is such that a histogram of the fibroblast
population’s stim (N) levels superimposed upon Figure 4 produces a skewed bell curve of
stim levels traveling to the right of this graph with respect to time, causing progressively
more agents to become AFibs, then MFibs, SFibs or dead agents.

Results
Metabolic Response
To increase the physiological relevance of our model and facilitate the
incorporation of an epithelial layer within future iterations, we wished to use a dosage of
CSC which would allow us to view an effect in both lung fibroblast and epithelial cells
without killing too many cells. Previous studies have tested the effects of CSC in both
fibroblasts and epithelial cells with dosages ranging from below 1 µg/ml 133,134 to over 1
mg/ml 135; however to our knowledge it had not been tested on NHLF or DHLF in vitro.
To evaluate the effect of CSC on NHLF metabolism and screen for dosage to use with the
rest of our experiments, we performed MTT assays and chose 50 µg/ml (0.125% v/v) CSC
for all future experiments since this dosage produced the largest increase in cell
metabolism without inducing cell death (data not shown). On a log scale, this dosage sits at
the midpoint of dosages evaluated across both cell types in the literature and corresponds
with values tested among both fibroblasts 15 and epithelial cells 136–138. However, this was
the lowest dosage used on lung fibroblasts in the literature 15,33,66,135,139. This dosage was
diluted within serum-free FBM and termed cigarette smoke media (CSM). To evaluate the
effect of each of our treatment medias on NHLF metabolism and ensure that the effect of
CSM was not due to its DMSO content, we performed a CCK8 assay (Figure 4.1). Overall,
metabolic changes were modest; yet a statistically significant difference was found
41

42
between FGM and CSM at 24 hours. Given the absence of statistical differences between
CSM and either of its vehicle controls, we concluded CSM was not mimicking DMSO
exposure.
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Figure 4.1 – Metabolic responses of normal human lung fibroblasts exposed to either
FGM, FBM, CSM or 0.125% DMSO over 24 hours. Data is shown as the mean ± SD of
sextuplicate wells. Significant statistical differences are noted with * where p<0.05.
Within-group comparisons with baseline (time = 0) are indicated above the error bar and
between-group comparisons within each time-point are indicated with a horizontal line.
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Scratch Wound Closure
To evaluate the wound healing response of lung fibroblasts in vitro, NHLF and
DHLF were grown to a confluent monolayer then scratched to mimic a tissue injury and
observed as the cells invaded and re-covered the denuded region over 24 hours (Figure
4.2). In general, fibroblasts made statistically significant progress after 12 hours in all
conditions except for DHLF treated with CSM. NHLF under all conditions also made
statistically significant progress between 12 and 24 hours post-scratch, however DHLF’s
progress was less significant. NHLF treated with FGM often achieved 90% closure after
24 hours; however, at all time-points this rate of healing was significantly impaired when
fibroblasts were deprived of serum, exposed to CSM, and/or derived from COPD patients.
A significant difference was also found between FBM and CSM exposures after 24 hours
among NHLF, but not DHLF, indicating that DHLF could be resistant to 50 µg/ml CSC
(Figure 4.3).
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Figure 4.2 – Phase contrast images of NHLF and DHLF closing a scratched monolayer
over 24 hours while exposed to either FGM, FBM or CSM in vitro. Scale bar = 200 µm.
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Figure 4.3 – In vitro scratch closure data of NHLF or DHLF monolayers exposed to FGM,
FBM or CSM over 24 hours. Data is expressed as the percentage of the initial scratched
area re-covered by cells (%Healed); shown as the mean ± SEM of N ≥ 4 biological repeats.
Significant statistical differences are noted with * where p<0.005, *** where p<0.005 and
**** where p<0.0001. Between-group comparisons within each time-point are indicated
with a horizontal line.

The calibrated parameter-sets were found to fit within two standard deviations of
the in vitro mean scratch closure at every time-point measured, even though the model was
not being evaluated with the 4 hour time-point (Figure 4.4). The parameter-sets also fit
within one standard deviation of the mean at most time-points for most groups (data not
shown); such was the case for NHLF treated with FBM or CSM at all time-points – as well
as NHLF treated with FGM, or DHLF treated with FBM, at all time-points after 8 hours.
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Figure 4.4 – Simulated transients and in vitro scratch closure data of NHLF and DHLF.
Shown are NHLF (circles, left column; N = 3-11) or DHLF (stars, right column; N = 1-4)
responses to FGM (green), FBM (blue) or CSM (red) while closing a scratched monolayer
over 24 hours; expressed as the percentage of the initial scratched area re-covered by cells
(%Healed). In vitro data (markers with error bars) is shown as mean ± 2SD of N biological
repeats. Simulated transients were calculated by taking the mean and standard deviation of
10 simulations using the same initial conditions and parameter-set calibrated for each cell
type and media exposure (Table 4.1); means are plotted with a solid curve and standard
deviations are depicted by a shaded region around the mean curves.
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Total Population
To evaluate NHLF proliferation during a scratch assay with each treatment in vitro
and generate a dataset representing cell population to fit against the model, the total cell
population measured in each in vitro cell stain assay was pooled together after first being
normalized. The average cell count data was first normalized by (1677 µm)2 to account for
differences in cell count between the different areas measured by the two cameras and the
model area, then this was normalized to the baseline cell density at the start of either the
pre-scratch or post-scratch interval to account for differences between the in vitro seeding
densities for the scratch assays and stain assays.
Overall, changes in the cell density data were modest over the 24 hours postscratch, with only NHLF treated with FGM showing a significant difference from baseline
after 24 hours, at which point it was also significantly different from the other treatments
(Figure 4.5). There was a large amount of error within this dataset that may have masked
other differences being revealed, and this may have also undercut its use as a dataset to fit
the model against. The calibrated parameter-set for NHLF treated with FGM was able to fit
the in vitro data within one standard deviation of the mean in both the pre-scratch and postscratch intervals until 24 hours post-scratch, which still fell within two standard deviations.
The other calibrated parameter-sets fit within one standard deviation of their in vitro means
(Figure 4.6).
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Figure 4.5 – In vitro cell density among NHLF exposed to FGM, FBM or CSM while
closing a scratched monolayer over 24 hours. Data is expressed as the number of cells per
(1677 µm)2; shown as the mean ± SD of three independent assays normalized to baseline.
Significant statistical differences are noted with * where p<0.05 and **** where p<0.001.
Within-group comparisons with baseline (time = 0) are indicated above the error bar and
between-group comparisons within each time-point are indicated with a horizontal line.

Cell Death & Viable Subpopulation
To determine the percentage of cell death among NHLF during a scratch assay with
each treatment in vitro and generate datasets to fit the model against, cell monolayers were
scratched and subsequently stained with fluorescent dyes to mark live and dead cells
(Figure 4.7). Surprisingly, the ratio of dead cells significantly decreased from baseline after
only 12 hours post-scratch in all conditions, at which point the percentage of cell death was
below 5% of the population and showed no differences between treatments (Figure 4.8).
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Figure 4.6 – Simulated transients and in vitro cell density data among NHLF. Shown are
responses to FGM (green), FBM (blue) or CSM (red) during the 8 hour pre-scratch interval
(top left plot) or while closing a scratched monolayer over 24 hours (top right and bottom
plots); expressed as the number of cells per (1677 µm)2. In vitro data (markers with error
bars) is normalized to baseline and shown as the mean ± 2SD of 3 independent
experiments. Simulated transients were calculated by taking the mean and standard
deviation of 10 simulations using the same initial conditions and parameter-set calibrated
for each cell type and media exposure (Table 4.1); means are plotted with a solid curve and
standard deviations are depicted by a shaded region around the mean curves.

Due to the negligibly low percentage of cell death, inability of the model to fit this
viability data along with the proliferation data (not shown), and lack of a direct method to
reduce the percentage of dead cells, this data was excluded as a calibration-set for the
model.
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Figure 4.7 – Fluorescent stain of live (green) and dead (red) NHLF exposed to FGM, FBM
or CSM while closing a scratched monolayer over 24 hours in vitro. Scale bar = 200 µm.

Senescent Subpopulation
To determine the percentage of cell senescence among NHLF during a scratch
assay with each treatment in vitro and generate datasets to fit the model against, cell
monolayers were scratched and subsequently stained with chromogenic SA-β-Gal and
fluorescent DAPI to mark senescent cells among all the cell nuclei (Figure 4.9). As
expected, the ratio of senescent cells increased over the first 12 hours post-scratch;
however we were surprised to find the percentage returned to baseline levels over the
following 12 hours. After 12 hours, the percentage of senescence was significantly
increased over 2.5 among NHLF treated with FGM and nearly 2-fold with FBM treatment,
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but showed no change with respect to baseline when treated with CSM. However,
treatment with CSM did show more error in the data, potentially indicating a masked effect
that may be uncovered with repeated experiments. This was reflected in the statistically
significant differences found between FGM and both other treatments at 12 hours postscratch when no difference was found between FBM and CSM treatments (Figure 4.10).
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Figure 4.8 – In vitro percentage of dead cells among NHLF exposed to either FGM, FBM
or CSM while closing a scratched monolayer over 24 hours. Data is expressed as the
percentage of dead cells among all living and dead cells; shown as the mean ± SD of
quadruplicate wells. Significant statistical differences with all other groups are noted above
the error bar with *** where p<0.0005.

52

0 HR

12 HR

24 HR

NHLF

FGM

FBM

CSM
Figure 4.9 – Superimposed channels of chromogenic SA-β-Gal (cyan) and fluorescent
DAPI (magenta) stained NHLF exposed to FGM, FBM or CSM while closing a scratched
monolayer over 24 hours in vitro. Scale bar = 200 µm.

Due to the lack of evidence in the literature supporting reversible senescence and
the inability of the model to decrease the level of senescence outside of cell death (shown
above to be negligible), the 24 hour time-point was excluded from the dataset used to
calibrate the model. The calibrated parameter-set for NHLF treated with FGM was able to
fit the in vitro data within one standard deviation of the mean except for the 8 hour timepoint in the pre-scratch interval, which still fell within two standard deviations. The
calibrated parameter-sets for NHLF fit within one standard deviation of the in vitro means
for CSM treatment, but only fit within two standard deviations for FBM treatment, in part
due to the relatively large error within the in vitro data for CSM treatment (Figure 4.11).
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Figure 4.10 – In vitro percentage of senescent cells among NHLF exposed to either FGM,
FBM or CSM while closing a scratched monolayer over 24 hours. Data is expressed as the
percentage of SA-β-Gal stained cytoplasms among DAPI stained nuclei; shown as the
mean ± SD of quadruplicate wells. Significant statistical differences are noted with **
where p<0.01 and **** where p<0.001. Within-group comparisons with baseline (time =
0) are indicated above the error bar and between-group comparisons within each time-point
are indicated with a horizontal line.

Myofibroblast Subpopulation
To determine the percentage of myofibroblasts among NHLF during a scratch
assay with each treatment in vitro and generate datasets to fit the model against, cell
monolayers were scratched and subsequently stained with fluorescent anti-αSMA
immunocytochemistry and DAPI to mark myofibroblast cytoskeletons among all cell
nuclei (Figure 4.12). The percentage of myofibroblasts remained consistent with baseline
at 10-20% when treated with FGM or FBM over 24 hours, however CSM treatment was
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found to induce a statistically-significant, approximately 3-fold increase of myofibroblasts
that returned to baseline by 24 hours (Figure 4.13).

Figure 4.11 – Simulated transients and in vitro senescence data among NHLF. Shown are
responses to FGM (green), FBM (blue) or CSM (red) during the 8 hour pre-scratch interval
(top left plot) or while closing a scratched monolayer over 24 hours (top right and bottom
plots). In vitro data (markers with error bars) is shown as the mean ± 2SD of quadruplicate
wells. Simulated transients were calculated by taking the mean and standard deviation of
10 simulations using the same initial conditions and parameter-set calibrated for each cell
type and media exposure (Table 4.1); means are plotted with a solid curve and standard
deviations are depicted by a shaded region around the mean curves.

The calibrated parameter-set for NHLF treated with FGM was able to fit the in
vitro data within two standard deviation of the mean percentage of myofibroblasts in both
the pre-scratch and post-scratch intervals at all time-points, even falling within one
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standard deviation after 12 and 24 hours post-scratch. The other calibrated parameter-sets
fit within two standard deviations of their in vitro means, except for the 12 hour postscratch time-point for FBM parameter-set (Figure 4.14).
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Figure 4.12 – Superimposed fluorescent channels of αSMA (red) and DAPI (blue) stained
NHLF exposed to FGM, FBM or CSM while closing a scratched monolayer over 24 hours
in vitro. Scale bar = 200 µm.

Among the parameter-sets screened, parameter-sets which fit the 12 hour timepoint of the FBM in vitro data were not also able to fit the 24 hour time-point because the
transients that fit either time-point took opposing trajectories that excluded the other. All of
the transients initialize with approximately 15% myofibroblasts due the preconditioning
step and the overall trend of the in vitro data for FBM treatment had a downward
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trajectory, so the calibrated parameter-set for FBM was chosen from parameter-sets which
fit the 24 hour time-point with a downward trajectory as opposed to the 12 hour time-point
with an upward trajectory (Figure 4.14).
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Figure 4.13 – In vitro percentage of myofibroblasts among NHLF exposed to either FGM,
FBM or CSM while closing a scratched monolayer over 24 hours. Data is expressed as the
percentage of DAPI-stained nuclei co-localized with αSMA-stained cytoskeletons among
all DAPI-stained nuclei and shown as the mean ± SD of quadruplicate wells. Significant
statistical differences are noted with **** where p<0.001. Within-group comparisons with
baseline (time = 0) are indicated above the error bar and between-group comparisons
within each time-point are indicated with a horizontal line.

Superimposed Subpopulations
Taken all together, our evaluation of NHLF subpopulations show a spike in either
myofibroblasts and/or senescent cells that returns to baseline or below by 24 hours, and that
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the overarching difference between treatment groups are represented by the magnitude and
relative composition of this spike. Cell death primarily occurred peri-scratch, ostensibly due
to the scratch itself, and was otherwise negligible. Cell proliferation was also found to be
negligible over 24 hours, with the exception of FGM treatment at the end of the 24 hour
period evaluated.

Figure 4.14 – Simulated transients and in vitro myofibroblast data among NHLF. Shown
are responses to FGM (green), FBM (blue) or CSM (red) during the 8 hour pre-scratch
interval (top left plot) while closing a scratched monolayer over 24 hours (top right and
bottom plots). In vitro data (markers with error bars) is shown as the mean ± 2SD of
quadruplicate wells. Simulated transients were calculated by taking the mean and standard
deviation of 10 simulations using the same initial conditions and parameter-set calibrated
for each cell type and media exposure (Table 4.1); means are plotted with a solid curve and
standard deviations are depicted by a shaded region around the mean curves.
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Figure 4.15 – Superimposed percentages of myofibroblasts, senescent cells and dead cells
among NHLF exposed to FGM, FBM or CSM during scratch closure. Data is expressed as
the mean ± SD of quadruplicate wells.

At baseline, approximately 40% of cells were either myofibroblasts or senescent.
While FGM and CSM treatments returned to this level by 24 hours, treatment with FBM
decreased to approximately 30% myofibroblasts or senescent cells. During the spike in
subpopulations found 12 hours post-scratch, FBM treatment subtly increased the
percentage of senescence and myofibroblasts to approximately 50% of cells with a
significant increase in the percentage of senescent cells (Figure 4.10) paired with an
insignificant decrease in the myofibroblast percentage. However, treatment with either
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FGM or CSM increased the baseline percentage of myofibroblasts and senescent cells
approximately 2-fold during this 12 hour spike. We also found that while FGM treatment
achieves this through an increase in the senescent subpopulation with negligible change in
myofibroblasts, CSM treatment achieves this through an increase of myofibroblasts with
minor changes in the senescent subpopulation (Figure 4.15).

Calibrated Parameter-Sets
The fibroblast wound healing model was evaluated through the analysis of 3000
distinct parameter-sets which produced a pattern of parameter-sets that fit the in vitro data
for total population, percentage of myofibroblasts and percentage of senescent cells, but
not scratch closure. Analysis of a further 100 parameter-sets with varied migration and
proliferation rates found 50 parameter-sets that fit within two standard deviation of all the
in vitro data for NHLF treated with FGM in both pre-scratch and post-scratch intervals,
however only one of these fit most of the in vitro data within one standard deviation when
evaluated with 10 simulations per parameter-set (data not shown). Therefore, this
parameter-set was chosen to represent NHLF treated with FGM and used to calibrate the
pre-scratch interval of the model by preconditioning the agents’ variables since all of the in
vitro scratch assays the model is fit against were incubated in FGM during the seed-scratch
interval. These are the parameters that govern the preconditioning of agent subpopulations,
stimulation levels and division rates during the pre-scratch interval. Another 256
parameter-sets were subsequently evaluated to find fits for the remaining experimental
groups (Table 4.1). All of the calibrated parameter-sets were found to share the same
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values for the magnitude of environmental stimulation (AM = 2*10-4 stim/hour) and
distribution of the fibroblast population’s sensitivity to stimuli (AS = 0.3). The parametersets that fit the in vitro data for NHLF treated with CSM also shared the same stimulation
thresholds for myofibroblast and senescent transitions (LM = 0.5 and LS = 0.3) as DHLF in
either condition.
Table 4.1 – Calibrated Parameter-Sets of the Fibroblast Responses.
NHLF
DHLF
Parameter
FGM
FBM
CSM
FBM
CSM
M

65

24

16

12

12

P

27

24

30

42

42

Ls

0.1

0.17

0.3

0.3

0.3

Lm

0.06

0.58

0.5

0.5

0.5

Am

2.00E-04

As

0.3

Table 4.1 caption – Calibrated parameter-sets which fit the in vitro responses of NHLF and
DHLF exposed to FGM, FBM, or CSM while closing a scratched monolayer over 24
hours. Simulated outputs were calculated by taking the mean and standard deviation of 10
simulations with the same initial conditions for each parameter-set. Simulated means
within two standard deviations of the in vitro mean were considered a fit for that output.

Overall, it was found that the experimental groups with slower scratch closure rates
had lower values of M, and higher values of P, LM and LS. In particular, lower ratios of
parameters M:P reliably produced slower closure rates. As expected from the model
design, lower values of LM were associated with more myofibroblasts, lower values of LS
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were associated with more senescent cells, and lower ratios of LM:LS were associated with
a sharper spike in the percentage of myofibroblasts (Figures 4.11 & 4.14).

Parameter Sensitivity Analysis
To evaluate the sensitivity of parameter modulations around each calibrated
parameter-set on the model outputs, we independently modulated each parameter by +/10% and calculated the percentage difference in each model output. As seen in Table 4.2,
up to 2 or 3-fold change in model outputs per unit change in model parameters could be
achieved for scratch closure, the percentage of senescent cells, and the percentage of
myofibroblasts. Sensitivity analysis results for other outputs are shown in Appendix C.
Notably, model responses were largely insensitive to modulations in the stimulation
parameters AM or AS within any of the calibrated-sets, with adjustments in the model
responses largely following the overall trend of adjustments due to modulations in the
other parameters.
As expected due to the low probability of death due to stimulation within the
model, modulating the parameters had minimal effect on the percentage of dead cells, with
a maximum increase of 7% cell death when the proliferation interval was increased with
the calibrated-set for NHLF treated with FGM. The large majority of parameter
modulations increased cell death, and this effect decreased among sets with slower scratch
closure rates. Increasing the division interval or decreasing the migration rate generated the
largest increase in cell death among all of the calibrated-sets, and this was almost always
associated with a concomitant decrease in the total population.
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Also as expected due to the relatively short time interval evaluated with respect to
the division intervals (parameter P) for these parameter-sets, modulating the parameters
produced ≤ 12.5% difference from the calibrated-sets’ total populations among all of the
calibrated-sets’ parameter modulations. However it was somewhat surprising to find that
most parameter modulations had a negative effect on the cell population, with the largest
increase of 5.1% more cells after 24 hours among the DHLF parameter-set attributed to
increasing the senescence threshold (Appendix C), which decreases the rate of senescence
within the model.
As expected from the model design and calibrated parameter-sets, increasing the
parameters for migration rate increased the scratch closure rate more than any other
parameter alone. As expected due to the robust healing response of NHLF treated with
FGM, differences in scratch closure due to parameter modulations within this calibratedset skewed negative; and those differences among calibrated-sets associated with lower
rates of scratch closure skewed increasingly positive. Many of the parameter modulations
were also found to produce differences in scratch closure 12 hours post-scratch that were
partially lost by 24 hours.
In general, the percentage of senescent cells and myofibroblasts were found to
increase more, or decrease less, with lower values of LS and LM, respectively; although
lower values of LS were also consistently correlated with a decrease in myofibroblasts.
Further illustrating the interdependence of these subpopulations within the model,
modulations in the calibrated-sets’ parameters that decreased the percentage of senescent
cells generally also increased the percentage of myofibroblasts and vice versa. Strikingly,
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modulations of any parameter in either direction within the calibrated parameter-set for
NHLF treated with FBM increased the senescent population by 20-30% at both 12 and 24
hours post-scratch while the myofibroblasts lost 0-10% and 15-25% of their population
after 12 and 24 hours, respectively. This also illustrates clearly how a spike in the
percentage of myofibroblasts can be created by adjusting the parameters such that more
myofibroblasts are formed at earlier time-points which subsequently become senescent by
the end of 24 hours (e.g. necessary to fit the calibrated-set for NHLF treated with FGM;
Figure 4.14), and how this effect can be used to adjust the time dynamics of the scratch
closure rates in a nonlinear manner.
Among the calibrated parameter-sets, NHLF treated with FGM was the least
sensitive to modulations in the parameters and showed a generally negative skew in the
scratch closure output accompanied with a proportionate boost in the percentage of
senescent cells and a flatter spike in the percentage of myofibroblasts 12 hours postscratch. The calibrated-set for NHLF with FBM also produced modest modulations in the
scratch closure rate, but these showed a consistent time-dynamic; parameter modulations
around this set typically increased scratch closure by 12 hours post-scratch, but this boost
was lost or reversed by 24 hours. As stated earlier, this mild boom-bust response in the
scratch closure rate due to parameter modulations was also accompanied with a large static
boost in the percentage of senescent cells along with a decrease in the percentage of
myofibroblasts that intensified with time. Taking into consideration the inability of the
calibrated-set for NHLF with FBM to fit both the 12 and 24 hour time-points of the in vitro
data for the percentage of myofibroblasts (Figure 4.14), the negative skew in the model’s
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myofibroblasts output indicates that up to ±10% modulation in any parameter would not be
able to fit this 12 hour time-point, all due to the same downward trend in myofibroblasts.
The calibrated-sets for either NHLF treated with CSM or DHLF were much more
sensitive to changes in the parameters, with the most drastic boost on the scratch closure
output being produced by increases in the migration parameter. Interestingly, the
calibrated-set for DHLF was found to be insensitive to the proliferation and transition limit
parameters while the calibrated-set for NHLF treated with CSC was found to be relatively
sensitive to these terms, despite these sets sharing the same values of LM and LS. This
illustrates how the values of some parameters (e.g. M, P) can influence the sensitivity of
the model outputs to the other parameters (e.g. LM, LS). Additionally, it was found that the
ratio of these parameters were as important as their raw values to find parameter-sets
whose outputs matched a given dataset; where the ratio of M:P had more of an effect on
the scratch closure rate while the ratio of LM:LS had more of an effect on the subpopulation
levels and nonlinearity of scratch closure.

Simulated Treatments for Smoke Exposure & COPD Fibroblasts
Since the results of our sensitivity analysis indicated an increase in the migration
rate would result in a faster rate of scratch closure among either cell line treated with CSM,
we performed simulations of these calibrated-sets with up to 3-fold higher migration rates
to represent potential treatments for these fibroblasts that could recover the scratch closure
response of NHLF in FBM (Figure 4.16). Although modulating other parameters were
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found to increase the scratch closure rate within the sensitivity analysis, intensifying these
modulations failed to increase the closure rate further (data not shown).

Figure 4.16 – Simulated treatments for NHLF and DHLF exposed to smoke. Transients of
parameter modulations around the calibrated-set (red) for NHLF (top) or DHLF (bottom)
treated with CSM that increase scratch closure (%Healed; brown-blue gradient). Transients
are juxtaposed with in vitro scratch closure data of NHLF (N = 3-6) or DHLF (N = 1-4)
exposed to CSM, shown as the mean ± 2SD of N biological repeats. Simulated transients
were calculated by taking the mean and standard deviation of 10 simulations using the
same parameter-set and initial conditions.
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Table 4.2 – Heat-map of each calibrated-set’s sensitivity to parameter changes.
Group
NHLF
FGM

NHLF
FBM

NHLF
CSM

DHLF

Parameter
Modulation
M
+
P
+
LM
+
LS
+
AM
+
AS
+
M
+
P
+
LM
+
LS
+
AM
+
AS
+
M
+
P
+
LM
+
LS
+
AM
+
AS
+
M
+
P
+
LM
+
LS
+
AM
+
AS
+
-

%Healed
12 HR
24 HR
0.4
0.8
-6.6
-5.4
-1.8
-1.0
-3.3
-5.5
-3.1
-1.5
-2.4
-3.3
-2.6
0.5
-2.9
-5.1
0.7
-3.1
-7.3
-3.6
-0.3
-0.8
-3.1
-4.3
8.8
0.9
-1.5
-9.1
4.9
-1.5
7.6
2.4
2.1
-0.7
9.4
-2.8
6.8
-1.8
2.3
-5.1
3.6
-2.8
5.4
-0.1
1.1
-4.7
6.7
-1.2
16.8
9.6
-3.7
-3.7
4.6
-0.1
9.4
8.4
-1.6
-0.4
7.4
5.2
7.6
5.8
5.3
2.5
8.0
6.7
9.8
6.0
4.0
-0.5
9.0
0.3
19.5
11.9
-2.7
-3.3
3.3
0.4
1.9
-0.3
3.7
1.5
-1.8
-5.6
-1.0
2.6
4.7
1.9
2.0
5.1
10.2
8.7
3.5
-0.2
7.6
7.2

%Senescent Cells
12 HR
24 HR
2.4
1.0
2.5
1.3
0.6
0.4
1.7
-0.2
2.1
1.2
1.3
1.2
-3.6
-3.7
5.1
4.2
4.9
3.1
-0.1
-2.6
2.2
0.8
2.8
0.4
21.7
22.9
23.5
25.0
24.7
26.0
24.9
25.2
19.9
23.6
25.6
25.9
19.4
18.4
28.6
30.9
26.9
28.8
21.6
19.3
21.7
21.8
23.2
23.6
4.6
1.2
1.0
-0.5
4.8
1.8
-0.1
-1.5
4.2
1.5
1.7
0.7
-4.9
-7.7
8.2
6.5
1.9
3.0
-1.1
-2.4
0.8
0.1
-0.9
-1.5
-2.0
1.7
-2.2
1.1
-0.8
-0.4
-2.0
-0.4
-4.2
0.1
1.2
2.8
-5.2
-5.0
-0.1
4.7
-3.9
0.5
-6.0
-5.4
0.3
3.3
-3.0
0.7

%Myofibroblasts
12 HR
24 HR
-0.9
2.2
-1.6
-0.2
-1.0
1.3
0.5
5.3
-4.3
-2.6
2.8
3.4
3.4
16.1
-2.6
-9.8
-0.5
-4.6
-3.5
9.9
-0.4
2.9
-2.4
2.2
-2.7
-19.9
-0.6
-20.2
-5.1
-21.7
-7.6
-24.9
-8.4
-24.8
-0.2
-16.9
-0.9
-15.8
-5.4
-26.6
-5.8
-21.9
-8.4
-18.8
0.0
-18.5
-8.8
-25.3
-5.9
-4.4
-4.8
-2.4
-5.2
-4.6
-3.3
-1.1
-9.8
-9.4
-3.3
-1.2
-3.7
-0.1
-5.1
-10.8
-1.6
-3.1
-6.1
-6.4
-6.8
-4.5
0.0
1.8
3.3
-1.3
-2.4
-1.8
-2.7
-0.5
2.0
4.9
-2.6
-3.4
2.7
6.0
2.0
8.5
1.7
-1.6
4.8
3.3
-1.2
3.7
-1.7
-2.8
2.0
1.6
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Table 4.2 caption (previous page): sensitivity of model outputs to parameter modulations
with respect to each calibrated parameter-set are expressed as the percentage difference
from the calibrated parameter-set’s mean output when each parameter is independently
modulated by ± 10%. Model outputs are shown for the percentage of scratch closure
(%Healed) and the percentage of senescent cells or myofibroblasts after 12 or 24 hours.
Parameter-set mean outputs were calculated from 10 simulations with the same
conditions. A blue-red gradient was applied across all outputs and parameter
modulations within each experimental group.
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Discussion
Differences among Normal Fibroblast Exposures
We selected a dosage of 50 µg/ml CSC within our CSM treatment media because
dosages of 250 and 1000 µg/ml were found to cause 50-80% decrease in metabolism by
MTT assay (N = 1-2; not shown), which we interpreted as cell death and aimed to avoid
within our experiments in order to evaluate CSC’s effect on fibroblast functions, rather
than its effect on apoptosis; and we confirmed a significant difference between NHLF
treated with FGM versus CSM by CCK8 assay (Figure 4.1). However, considering that
both of these assays depend on NADH/NAD metabolism and CSC is also known to induce
oxidative stress associated with elevated NADH/NAD ratios, we had to confirm we were
avoiding cell death using a non-metabolic assay.
Our avoidance of large drops in metabolism is likely why we found ≤ 10% dead
cells at any of the time-points we evaluated in our cell stain experiments; however it was
surprising to find that the percentage of cell death decreased over time at a rate which we
were unable to match with the model while also fitting the population data for NHLF
treated with FGM (not shown), indicating that the percentage of dead cells in vitro were
being decreased directly. Upon re-evaluating the literature to confirm this result, we found
reports that fibroblasts participate in efferocytosis to clear dead cells and debris during
wound closure as one of their many roles in tissue maintenance 140,141. Since our in vitro
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data contained negligibly low levels of cell death, we simply left this out of our model;
however, future iterations of the model that aim to evaluate fibroblast responses involving
more cell death than this iteration should include a rule for this functionality to ensure this
model output is relevant to in vitro measurements to which it’s fit.
While intriguing, any conclusions drawn from interpretations of this in vitro
population data are unfortunately limited by the lack of biological repeats. Also, the
senescence and myofibroblasts assays each suffered from limitations in their measurement
that likewise limits the confidence in conclusions drawn from them. The SA-β-Gal assay
used to evaluate the percentage of senescent cells can induce a false positive among
quiescent cells, particularly fibroblasts in confluent monolayers such as those used within
the scratch assays. Thus, the seeding density of all the cell stain experiments were lowered
in order to minimize the probability of false positives within the senescence assay and
perform these experiments with the same conditions to preserve the cells’ level of contact
inhibition within the stain experiments; and this adjustment in the seeding density may
have compromised our assessment of the subpopulations within the scratch closure
experiments. Also analyzing the DAPI stain for senescence-associated heterochromatic
foci could have served as a control against quiescent cells 130, however the large degree of
background fluorescence within this stain limited our ability to do this analysis. The
immunocytochemistry assay of αSMA expression also suffered from pervasive background
fluorescence that limited the image contrast available for image processing, such that the
percentage of myofibroblasts may have been systematically over-reported. These
limitations are highlighted by our observation of less cell senescence following a spike in
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senescence 12-hours post-scratch among NHLF treated with FGM; while anecdotal reports
of reversible senescence exist 142, these have not yet passed peer review. As mentioned
earlier, the model was not required to match a decrease in cell senescence at the 24 hour
time-points for this reason. Despite any concerns regarding the accuracy of the in vitro
subpopulation data, calibrated parameter-sets were able to match both the percentage of
myofibroblasts and senescent cells along with scratch closure rates with few exceptions
(Figure 4.14).
Our scratch wound closure assays revealed that NHLF exposed to each media type
produced a significantly different scratch closure rate from the others 24 hours postscratch, and each of these closure responses was characterized by a unique dynamic in the
cell subpopulations that was supported by the calibrated parameter-sets for these groups.
The relatively short time evaluated by the model with respect to these cell types mean
division intervals (parameter P) limits our ability to find significant differences in this
parameter between experimental groups. Additionally, we found that regardless of cell
type of media exposure, all experimental groups were associated with calibrated-sets
containing the same values for the parameters governing the magnitude of environmental
stimulation (parameter AM) and heterogeneity of individual responses to a given type or
level of stimulation among the population of fibroblast (parameter AS).
With respect to the calibrated parameter-set for NHLF treated with FBM, treatment
with FGM was associated with a 2.4-fold increase in migration rate paired with a 9.7-fold
higher rate of myofibroblast activation compensated by a 1.7-fold higher rate of
senescence. Despite the spike in senescence associated with negligible myofibroblast
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increase that we found in vitro and matched in silico, this calibrated-set still indicates a
drastic enhancement of migration and myofibroblast activation due to the inclusion of
serum, bFGF and insulin to their media – which makes sense considering these ingredients
are included in FGM to enhance fibroblast migration, proliferation and activation via the
Wnt/β-catenin pathway 143 or Akt1, myocardin and serum response factor 144 . Notably,
bFGF has also been found to deactivate myofibroblasts when stimulated by TGFβ, both
mediated by Akt1 144, which supports our in vitro finding of mildly elevated
myofibroblasts that returned to baseline over 24 hours.
With respect to the calibrated parameter-set for NHLF treated with FBM, treatment
with CSM was associated with a 33% drop in migration rate paired with a 16% higher rate
of myofibroblast activation compensated by a 44% lower rate of senescence. This indicates
an inhibition of NHLF migration rate independent to the loss in migration rate expected
from the concomitant increase in myofibroblasts with less senescent cells; however, this
calibrated-set was nearly 2 standard deviations from the mean of the in vitro data for the
percentage of myofibroblast, so the independent decrease in migration rate found in this
calibrated-set may be compensating for this lack of myofibroblast activation in order to fit
the scratch data. This is supported by reports showing that fibroblast activation is
stimulated by oxidative stress, such as is found within cigarette smoke 60.
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Differences between Normal & COPD Fibroblasts:
Many aspects of this project were influenced by the limited availability of DHLF,
as they only maintained log-growth for one or two passages; so one of the main goals of
the project was to use the model and in vitro scratch closure data for this cell line to
evaluate how DHLF functions may differ from NHLF and inform future investigations into
this cell line. For this reason, dosages of CSC were not tested among DHLF to ensure the
chosen dose produced an effect within both cell lines – which may have prevented us from
evaluating how DHLF responses to CSC differ from NHLF – however, our in vitro scratch
results show that DHLF is resistant to CSC relative to NHLF. In support of this finding,
the calibrated-set for DHLF was found to fit the DHLF in vitro data when exposed to
either FBM or CSM.
The limited availability of in vitro datasets of DHLF population responses to fit the
model against – or of DHLF exposed to FGM – also produced two problems. First, this
required the model’s preconditioning parameters for both cell lines to be calibrated using
in vitro data of NHLF and created an unlikely assumption within the model that DHLF
responses to FGM were the same as NHLF during the pre-scratch interval. Second, there
were many more parameter-sets that could have been classified as a calibrated-set among
DHLF since there were less datasets available to filter out sets that were not biologically
relevant to this cell line. Therefore, in order to use this forced assumption as a tool in our
comparison of these groups and help guide our selection of the calibrated-sets for DHLF,
we fit the model to both of these groups while maintaining the LM and LS parameters
between these sets and the calibrated-set for NHLF treated with CSM. This allowed us to
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use the calibrated-set for NHLF treated with CSM as a reference parameter-set that
assumed no difference between these cell lines’ subpopulation responses and limited the
variation between these sets to the migration and proliferation parameters.
Since the scratch closure response showed some sensitivity to all of the parameters
while the population levels were relatively insensitive to the migration and proliferation
parameters (Table 4.2) – and since the different subpopulations exhibit different migration
and proliferation rates (Figure 3.4) – variations in these parameters between the calibratedsets for DHLF and NHLF exposed to CSM suggest how the subpopulation levels may
change between these groups. Both the migration rate and proliferation rate were found to
be lower among DHLF calibrated-sets relative to NHLF treated with CSM, which may
indicate either (A) these cells migrate and proliferate less due to a fundamental (e.g.
genetic, epigenetic) difference between these cell lines, (B) there are more myofibroblasts,
(C) there are more senescent cells, or (D) some combination of these. It is impossible to
speculate upon the likelihood of genetic differences among DHLF using this analysis of
the model, as these kinds differences may produce a relative increase in myofibroblasts or
cell senescence; however, we can infer from the relatively equal decrease in migration and
proliferation parameters – down to 72-75% of the values for the set calibrated to NHLF
treated with CSM – that this difference is likely due to an increase in the percentage of
myofibroblasts rather than senescent cells. Since senescent cells lose the ability to
proliferate or migrate in a directed manner, we would expect more of a decrease in both of
these terms, particularly the proliferation rate; however future simulations repeating this
analysis while holding the migration and proliferation parameters constant, or letting them
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all vary together, could be used to test this hypothesis in silico prior to in vitro
investigations.
Taking these findings into consideration with the years of smoke exposure typically
needed to produce COPD symptoms, a more holistic interpretation of DHLF’s significant
decrease from NHLF closure rates, insensitivity to CSM in vitro and in silico, and relative
decrease in migration and proliferation rates in silico suggest that DHLF represents a
subpopulation of NHLF that had survived a selection process for resistance to cigarette
smoke and upregulated the percentage of myofibroblasts. This interpretation is supported
by our in vitro finding that NHLF exposure to CSM induced a spike in the percentage of
myofibroblasts after 12 hours.
Since in vivo wound healing and homeostasis is an orchestrated process requiring a
balance of multiple native cell types, our interpretation that COPD pathogenesis is at least
in part due to an upregulation of fibroblasts relative to other cell types due to selective
pressures of oxidative stress caused by chronic smoke exposure is supported by the
distribution of tissue degradation and fibrosis within COPD. Elevated proportions of
epithelial and endothelial cells to native fibroblasts within parenchymal regions relative to
the bronchioles among normal lungs, paired with a chronically elevated rate of
mesenchymal transitions, would be expected to result in the pattern of tissue loss and
fibrosis seen in each respective region among COPD lungs. Luckily, the autoflourescence
of NADH may be used as a biomarker of oxidative stress and metabolic health in future
studies of this mechanism 145.
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Simulated Treatments for Smoke Exposure & COPD Fibroblasts
Our sensitivity analysis and following simulations of increasing modulations of
individual parameters around the calibrated-sets for DHLF and NHLF treated with CSM
found that an increase in the migration parameter alone would continue to increase the
scratch closure rate the more it was elevated (Figure 4.16), but increasing modulations in
the other parameters alone had practically no effect (data not shown). It is unlikely that a
potential in vitro treatment would affect migration rate without also affecting other
pathways due to the degree of crosstalk among cellular signaling pathways; however, since
the model is sensitive to modulations in ratios of parameters more than individual
parameters, further simulations of parameter modulations of multiple parameters around
these calibrated-sets are likely to reveal more potential treatments for these groups.
Regardless, increasing fibroblast migration rates should be achievable in vitro through
several means (Table 5.1). Increased migration should be achievable by drugs which
increase actin expression, actin treadmilling, microtubule stabilization, Rho/Rac signaling
or inhibition of contractility. Additionally, increased migration via decreased contractility
could be achieved with less myofibroblasts, which in itself would be achievable by
treatments which limit their activation, induce their deactivation, or induce senescence –
once such mechanism to accomplish this would be to supplement with bFGF to induce
deactivation and promote senescence as was seen in our in vitro experiments among NHLF
treated with FGM. Counteracting the cigarette smoke induced oxidative stress to prevent
the associated increase in myofibroblasts may also represent a valid strategy – this could
be achieved directly through supplementation with an antioxidant such as vitamin C, and
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potentially protected against if cell-native antioxidants are primed prior to smoke exposure.
Likewise, caloric restriction or drugs which mimic this (e.g. glycolysis inhibitors,
glutaminolysis inhibitors, etc.) could be used to buffer NADH/NAD levels to minimize the
effect of oxidative signaling on downstream targets; and these downstream targets (i.e.
SIRT-1 and HIF-1α) can be inhibited directly to prevent upregulation of mesenchymal
marker genes (e.g. αSMA) or senescence. Finally, a recent review indicates various
interleukin inhibitors as another promising method to treat COPD by targeting the NLRP3
inflammasome theorized to drive the autoinflammatory processes observed in COPD 16.

Additional Functionality & Future Directions for the Model:
The aspects of the model explored here are not comprehensive. Our results may be
expanded upon with the model through a thorough evaluation of the parameter space that
fits each cell type and media exposure to judge if another parameter-set may represent a
better fit for the in vitro data than those presented, or to evaluate if modulations of more
than one parameter may produce synergy to improve scratch closure. However, high
performance computing resources are recommended for more intensive analyses or models
due to the number of simulations required, paired with NetLogo’s computational
inefficiency compared to other ABM platforms 114,115. Additionally, while this model was
weakly validated when it was found to fit the 4 hour time-point of the scratch closure data,
in vitro data sets of the DHLF subpopulations or of scratch closure to 48 hours post-scratch
could validate if our model and calibrated parameter-sets have predictive value.
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The availability of in vitro data sets from other fibroblast lines, media exposures or
other types of collective migration experiments would allow this model to be applied
towards additional questions. While we present here a model of fibroblast scratch closure,
the scratch and non-scratch regions could easily be switched to model a barrier removal
assay to evaluate differences in contact inhibition among the cell types and exposures with
less influence from cytokines released from damaged cells or the population of cells across
the scratch. Migration following cytokine gradients were not modeled, so different values
in the migration parameter required to fit data for these in vitro experiment types may
reveal the presence of such gradients and if DHLF and/or CSM responses are less sensitive
to these gradients. Additionally, data from migration assays for other cell lines (e.g. IPFfibroblasts, mesenchymal stem cells, cancer-associated fibroblasts) or exposures (e.g. Ecigarettes, H2O2, TGFβ) would allow the model to evaluate differences in those cell types
or exposure responses. Assays of these fibroblasts exposed to conditioned media from
normal or COPD-derived epithelial cells or macrophages would create parameter-sets
representing fibroblast responses to paracrine signaling from these cell types. Similarly,
assays of these fibroblasts on polyacrylamide gels of lung-relevant stiffnesses coated with
ECM from normal and COPD lungs could be used to generate parameter-sets representing
fibroblast responses to these substrate properties and vice versa. These parameter-sets
would allow differences in paracrine and cell-substrate signaling mechanisms within the
lung during smoking or COPD to be evaluated and would inform future model iterations
that include these cell types and mechanical features. For example, ECM composition and
stiffness could be modeled as patch variables that the fibroblast agents can interact with
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and differentially modulate based on their breed – this data could be fit against in vitro data
of fibril formation during the in vitro assays of fibroblasts on ECM-coated polyacrylamide
gels, or simulated from other models of fibril formation 146 or fibrosis 113 – while another
layer of patches and breed of agents could be included to model interactions with a layer of
epithelial cells and patrolling macrophages 112, respectively. However, these would take
exponentially more time to simulate with the number of patches or agents, so a modular
approach, high performance computing resources and/or more computationally efficient
modeling platforms are recommended 115,118.
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Table 5.1 – Potential Treatment Strategies for COPD and Smoke Exposure.
Treatment
Method
Therapy/Drug
Citation
Strategy
147
Stabilize microtubules
Paclitaxel
& cell polarity
84,148
↑ Actin content
Glucocorticoids
84
↑ Actin dynamics
Heat, CalyculinA
149
↑ Adhesion dynamics
Fasudil, Y27632
(via ROCK)
29,100,149
Increase
Fasudil, Y27632,
↓ Senescent induction
Migration
Rapamycin, Rapalogs
150
Dasatinib, Quercetin,
↓ Senescent population
Fisetin, Navitoclax,
(senolytics)
Venetoclax,
42,60,147,151–
Roflumilast, Piclamilast,
↓ Contractility &
154
Aclidinium, SMIFH2,
myofibroblasts
NOX4 inhibitors
144
↓ Activation
anti-Akt
Inhibit
144
Myofibroblasts ↑ Deactivation
bFGF
16
anti IL-1beta
Canakinumab
Inhibit
16
anti IL-1Ralpha
Anakinra
Inflammation
16
IL-1 trap (mock receptor) Rilonacept
29,60,155,156
↑ antioxidants
Vitamin C
29,157,158
caloric restriction
2DG (anti-glycolysis)
Counter
29,159,160
SRT2172, SRT1720
CSC & ROS
29,159,160
↑ SIRT1 / ↓ HIF-1α
Reservatrol
29,160
Metformin
Table 5.1 caption – Potential strategies, methods and specific therapeutics that may achieve
increased scratch closure among DHLF or NHLF exposed to cigarette smoke. Our model
suggests scratch closure will be most improved with increased migration rates, which can
be also accomplished by decreasing levels of senescence and myofibroblasts. Lower levels
of these cells may also be achieved through inhibition NLRP3-mediated inflammation or
countering the effects of oxidative stress from cigarette smoke.

80

Conclusions
We designed a model that captured the dynamics of fibroblast scratch closure due
to changes in myofibroblast activation and cell senescence and calibrated parameter-sets to
in vitro data for human lung fibroblasts exposed to cigarette smoke. Our in vitro results
and calibrated parameter-sets recapitulated findings of increased myofibroblast activation
and senescence among lung fibroblasts exposed to smoke or when derived from COPD.
Calibrated-sets for this model could be fit to in vitro data of other fibroblast lines or
exposures to evaluate their effects on scratch closure to investigate other diseases,
paracrine signaling with other cell types, potential toxins like E-cigarette vapor, or
therapeutics. Future iterations addressing COPD should work towards evaluating the
dynamics of myofibroblast activation on regulation of the ECM during wound healing
through traction forces and protease/antiprotease secretion mediated by oxidative stress.
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APPENDIX A
;; NETLOGO MODEL FOR IN VITRO FIBROBLAST WOUND HEALING
;; VERSION 1.2 - updated 03/23/2018
;; BY JAMES ALEX RATTI
;===============================================================|
;; VARIABLE & CONSTANT DEFINITIONS
globals [
Iheight ; in vitro image height
maxC ; modeled world's max coordinate (sets resolution)
ds
; patch length (=image size/101)
; { Patch Area = (101)^2 patches, due to origin + axes }
; { correlates to cropped image size of 1677x1677 um }
dt ; step interval (arbitrary)
; { model functions in step intervals = dt * tick }
; { such that there will be '1/dt' steps per tick. }
; { tick units = hours (arbitrary)
}
; { b/c model timer only counts ticks in whole numbers }
time_SS ; in vitro seed-scratch time for scratch assays
; { mean+/-sd of in vitro seed-scratch times = 14+/- }
I_AR ; in vitro image area (frm 2244.6x1677.0 for square dim.)
Rs_AR ; in vitro mean scratch area @ t=0, from all assays
Rc_AR ; in vitro cell-covered area
%s_AR ; in vitro ratio of scratched area to cropped image area
Vs_AR ; virtual scratch size [patches]
Scratch_width ; num. full rows per side (excluding center)
Scratch_center ; num. patches in filled rows
Scratch_edges ; num. patches in unfilled rows (ragged edge)
Scratch ; virtual initial scratched region (patch-set)
Healed ; virtual healed region (patch-set)
UnHealed; vitrual unhealed region (patch-set)
UnHealed_edge ; virtual unhealed region's border (patch-set)
Edge_length_t0 ; unhealed region's est. border length @t=0 [um]
Cell_AR ; individual cell area (assumed circular)
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N_diam ; in vitro diameter for NHLF
; selected* to fit cells w/ and w/o aSMA, within 1SD
; { *lit. avg
= 35.8+/-7.0 um (with aSMA)
}
;{
= 25.7+/-5.8 um (without aSMA)
}
Pop_Sm ; initial agent population, der. from seeding density
; { derived from in vitro seeding density for MTTs }
; { Pop_S = Pop_S*(IPop_S + APop_S + SPop_S)
}
Pop_Ss ; initial agent population, der. from seeding density
; { derived from in vitro seeding density for scratches}
; { Pop_S = Pop_S*(IPop_S + APop_S + SPop_S)
}
Pop_Ss6 ; agent population at t=seed+6
IPop_S ; initial population ratio of inactive fibs @t=seed+6
APop_S ; initial population ratio of activated fibs @t=seed+6
MPop_S ; initial population ratio of myo-fibs @t=seed+6
SPop_S ; initial population ratio of senescent fibs @t=seed+6
DPop_S ; initial population ratio of dead fibs @ t=seed+6
Pop_A ; initial agent population, der. from cell areas
; { derived from approx. confluency and cell diameter }
; { Pop_A = Pop_A*(IPop_A + APop_A + SPop_A)
}
IPop_A ; initial population ratio of inactive fibs @confluency
APop_A ; initial population ratio of activated fibs @confluency
MPop_A ; initial population ratio of myo-fibs @confluency
SPop_A ; initial population ratio of senescent fibs @confluency
Pop_t00 ; initial seeded cell population, from Pop_S or Pop_A
Pop_t00I; initial population of inactive fibs
Pop_t00A; initial population of active fibs
Pop_t00M; initial population of myo-fibs
Pop_t00S; initial population of senescent fibs
Pop_t0 ; initial cell population on non-scratch areas, estimated
stim_max; 'stimulation' maximum (for scaling reference)
stim_Ta ; 'stimulation' threshold w 50% fibroblast activation per hr
stim_T-a; 'stimulation' threshold w 50% fib deactivation per hr
stim_Tm ; 'stimulation' treshold w 50% AFib->MFib transition per hr
stim_Ts ; 'stimulation' threshold w 50% fibroblast senescence per hr
Alpha_Z ; size coefficient for inactivate fibs
Alpha_M ; migration coefficient for inactivate fibs
Alpha_P ; prolif. coefficient for inactivate fibs
Alpha_D ; death coefficient for inactivate fibs
Beta_Z ; size coefficient for activated (proto-myo-)fibs
Beta_M ; migration coefficient for activated (proto-myo-) fibs
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Beta_P ; prolif. coefficient for activated (proto-myo-)fibs
Beta_D ; death coefficient for activated (proto-myo-)fibs
Gamma_Z ; size coefficient for myo-fibs
Gamma_M ; migration coefficient for myo-fibs
Gamma_P ; prolif. coefficient for myo-fibs
Gamma_D ; death coefficient for myo-fibs
Omega_Z ; size coefficient for senescent fibs
Omega_M ; migration coefficient for senescent fibs
Omega_P ; prolif. coefficient for senescent fibs
Omega_D ; death coefficient for senescent fibs
Fsize ; baseline fib diameter [patches]
IFsize ; IFib diameter [patches]
AFsize ; AFib diameter [patches]
MFsize ; MFib diameter [patches]
SFsize ; SFib diameter [patches]
IFsplit ; dist. req. for IFibs to divide (fnx. of diameter)
AFsplit ; dist. req. for AFibs to divide (fnx. of diameter)
MFsplit ; dist. req. for MFibs to divide (fnx. of diameter)
SFsplit ; dist. req. for SFibs to divide (fnx. of diameter)
IFmove ; dist. req. for IFibs to move (fnx. of diameter)
AFmove ; dist. req. for AFibs to move (fnx. of diameter)
MFmove ; dist. req. for MFibs to move (fnx. of diameter)
SFmove ; dist. req. for SFibs to move (fnx. of diameter)
Fstep ; baseline fib step size (ref = IFibs)
= Migration_rate*dt/ds
IFspeed ; IFib step size [patch/tick]
= Fspeed*Alpha_Z
AFspeed ; AFib step size [patch/tick]
= Fspeed*Beta_M
MFspeed ; MFib step size [patch/tick]
= Fspeed*Gamma_M
SFspeed ; SFib step size [patch/tick]
= Fspeed*Omega_M
t_life ; agent lifespan mean
= Death_rate
sd_life ; agent lifespan std dev
= t_life/3
t_div ; agent doubling time mean
= Prolif_rate
sd_div ; agent doubling time std dev
= t_div/3
; {mean+-sd = 33.2 +- 10.4 hrs (for NHLF in FGM) }
; {lit. source: [Mio et al. 1992]
}
m_stim ; agent stimulation rate mean
= Stim_mean
]
patches-own [
V1_score ; ratio of neighbors without an agent (excluding Apops) present (max=1)
V2_score ; average of neighbors' V1_scores (max=1)
]
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turtles-own [
Fspeed ; step size for fibroblast
fission ; countdown to fibroblast division (divide @ fission<=0)
life ; countdown to fibroblast rep-senescence (sen @ life<=0)
Zsense ; factor for sensitivity to stimuli
stim ; counter for fibroblast stimulation (min=0, max=1)
P_die ; probability of fibroblast death
P_senesce ; probability for fibroblasts to senesce due to stimuli
]
breed [ IFibs IFib ] ; INACTIVE FIBROBLASTS (mobile; solid/hollow triangles)
IFibs-own [
P_activate
; probability for inactivated fibroblasts to activate
]
breed [ AFibs AFib ] ; ACTIVE PROTO-MYO-FIBROBLASTS (mobile; solid/hollow
squares)
AFibs-own [
P_deactivate
; probability for activated fibroblasts to deactivate
P_transmyo
; probability for activated fibroblasts to become myofibroblasts
]
breed [ MFibs MFib ] ; MYO-FIBROBLASTS

(mobile; spade/club card symbols)

breed [ SFibs SFib ] ; SENESCENT FIBROBLASTS (mobile; g/b/r, solid/hollow circles)
breed [ Apops Apop ] ; DEAD CELLS / APOPTOTIC BODIES (immobile markers; white
stars)
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;================================================================|
;; MODEL INITIATION
to setup
clear-all
; SETS CONSTANTS FOR TIME/SPACE RESOLUTION
set maxC 50
; sets world's max coordinate = 50
patches
resize-world (-1 * maxC) maxC (-1 * maxC) maxC ; world size = 101*101 patches
set Iheight 1677
; in vitro image height
= 1677 um
set ds Iheight / world-height ; patch length
= 16.604 um/patch
set dt 20 / 60
; step interval
=[ 20 min/step]
set N_diam 30
; NHLF diameter
= 30
um
; SETS CONSTANTS FOR SCRATCH DIMENSIONS
set I_AR Iheight ^ 2
; in vitro image area
= 2812329 um^2
set Rs_AR 1296089.3932
; in vitro scratch area
= 1296089 um^2
set %s_AR Rs_AR / I_AR
; scratch area as ratio
= 0.4609
set Vs_AR round (%s_AR * world-height ^ 2); virt. scratch area = 4701 patches
set Rc_AR (I_AR - Rs_AR)
; in vitro cell-covered area = 1516240 um^2
set time_SS time_seed-scratch / dt ; in vitro seed-scratch time= 42
steps
; SETS CONSTANTS FOR STIM. FUNCTION & CELL-STATE TRANSITIONS
set stim_max 1
; stim maximum per hr
set stim_Ta 0.0001
; stim threshold(a) = lvl w 50% activation/hr
set stim_T-a stim_Ta
; stim threshold(-a) = lvl w 50% deactivation/hr
set stim_Tm 0.06
; myofib stim threshold
set stim_Ts 0.1
; senescence stim threshold
set Alpha_Z 0.75
; Inactive fib size coeff.
set Alpha_M 0
; Inactive fib speed coeff.
set Alpha_P 1
; Inactive fib proliferation period coeff.
set Alpha_D 1
; Inactive fib death period coeff.
set Beta_Z 1
; Activated fib size coeff.
set Beta_M 1
; Activated fib speed coeff.
set Beta_P 1
; Activated fib proliferation period coeff.
set Beta_D 1
; Activated fib death period coeff.
set Gamma_Z 1.4
; Myo- fib size coeff.
set Gamma_M .625
; Myo- fib speed coeff.
set Gamma_P 1.4
; Myo- fib proliferation period coeff.
set Gamma_D 1.4
; Myo- fib death period coeff.
set Omega_Z 2
; Senescent fib size coeff.
set Omega_M .75
; Senescent fib speed coeff.
set Omega_P 1000
; Senescent fib proliferation period coeff.
set Omega_D 1000
; Senescent fib death period coeff.
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; SETS CONSTANTS FOR CELL LINES AND MEDIA TREATMENTS
set-default-shape Apops "star"
set-default-shape IFibs "default" ; IFib shape
set-default-shape AFibs "square" ; AFib shape
set-default-shape MFibs "suit spade"; MFib shape
set-default-shape SFibs "circle" ; SFib shape
set Fsize (N_diam / ds)
; baseline diameter
= 1.8068 patches
set IFsize (Fsize * Alpha_Z)
; IFib diameter
= 1.8068 patches
set AFsize (Fsize * Beta_Z)
; AFib diameter
=
patches
set MFsize (Fsize * Gamma_Z)
; MFib diameter
=
patches
set SFsize (Fsize * Omega_Z)
; SFib diameter
=
patches
set Cell_AR (pi * (N_diam / 2)^ 2) ; NHLF cell area
= 706.86 um^2
set IPop_A 0.00
; Inactive fib ratio @ confl. = 0
set APop_A 0.74
; Active fib ratio @ confl. = 0.74
set MPop_A 0.15
; Active fib ratio @ confl. = 0.15
set SPop_A 0.11
; Senescent fib ratio @ confl. = 0.11
set IPop_S 0
; Inactive fib ratio @ t=seed+6 =
set MPop_S 0.0435
; Myo-fib ratio @ t=seed+6
=
set SPop_S 0.1191
; Senescent fib ratio @ t=seed+6 =
set DPop_S 0.0148
; Dead fib ratio @ t=seed+6
set APop_S (1 - Ipop_S - MPop_S - SPop_S - DPop_S);Active fib ratio @t=seed+6

; SETS PARAMS FOR MIGRATION, DIVISION, DEATH & STIM COUNTERS
set Fstep (65 * dt / ds) ; baseline fib speed = {NHLF*FGM} FOR PRE-COND.
set IFspeed Fstep * Alpha_M
; IFib speed
set AFspeed Fstep * Beta_M
; AFib speed
set MFspeed Fstep * Gamma_M
; MFib speed
set SFspeed Fstep * Omega_M
; SFib speed
set t_div 27 / dt
set sd_div t_div / 3

; division rate mean
; division rate st.dev. = {P} hrs

set t_life 40 * t_div
set sd_life 40 * sd_div
set m_stim 0.0002 * dt

; base lifespan mean = 40*{P} hrs
; base lifespan st.dev. = 40*{P} hrs
; 'stimulation' rate mean = {NHLF*FGM} FOR PRE-COND.

; INITIATES ("SEEDS") FIBROBLASTS
set Pop_A round (I_AR / Cell_AR) ; agent pop. @100%confl. = 3979 agents
set Pop_Ss round (4E5 * I_AR / 9.6E8); IV-det agent pop.($cr) = 1172 agents
set Pop_Sm round (2E4 * I_AR / 3.2E7); IV-det agent pop.(MTT) = 1758 agents
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if Seed_Density = "Max Confluency" [ ; seeds fibs @100%confl. ignoring overlaps
set Pop_t00 Pop_A
set Pop_t00I round(Pop_t00 * IPop_A)
set Pop_t00A round(Pop_t00 * APop_A)
set Pop_t00M round(Pop_t00 * MPop_A)
set Pop_t00S round(Pop_t00 * SPop_A)
]
if Seed_Density = "In Vitro" [
; seeds fibs @ in vitro seeding density:
if Experiment_Type = "Culture Cond." [ ; sets seeding density for 96wells
ifelse Seed_IFibs_Only? = true [set Pop_t00 Pop_Ss][
set Pop_t00 Pop_Ss
]
]
if Experiment_Type = "Scratch Healing" [ ; sets seeding density for 6wells
ifelse Seed_IFibs_Only? = true [set Pop_t00 Pop_Ss][
set Pop_t00 Pop_Ss
]
]
if Experiment_Type = "Barrier Removal" [ ; sets seeding density for 6wells
ifelse Seed_IFibs_Only? = true [set Pop_t00 Pop_Ss][
set Pop_t00 Pop_Ss
]
]
set Pop_t00I round(Pop_t00 * IPop_S)
set Pop_t00A round(Pop_t00 * APop_S)
set Pop_t00M round(Pop_t00 * MPop_S)
set Pop_t00S round(Pop_t00 * SPop_S)
]
ifelse Seed_IFibs_Only? = true [ ; seeds all agents in inactive state
ask n-of Pop_t00 patches [ sprout-IFibs 1 [ train_IFib ] ]
ask turtles [ set fission ((random-float 1) * t_div) ]
ask turtles [ set Zsense random-normal 1 0.3 ]
][
; seeds agent states by proportions
ask n-of Pop_t00I patches [ sprout-IFibs 1 [ train_IFib ] ]
ask n-of Pop_t00A patches [ sprout-AFibs 1 [ train_AFib ] ]
ask n-of Pop_t00M patches [ sprout-MFibs 1 [ train_MFib ] ]
ask n-of Pop_t00S patches [ sprout-SFibs 1 [ train_SFib ] ]
ask n-of round(Pop_t00 * DPop_S) patches [ Fib_apoptose ]
ask turtles [ set fission ((random-float 1) * t_div) ]
ask turtles [ set Zsense random-normal 1 0.3 ] ; {NHLF*FGM} for Pre-conditioning
]
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; INITIATES AGENTS AND VARIABLES (PRECONDITIONING)
ifelse Precondition? = true [ Precondition_Fibs
; re-initializing parameters to simulate post-scratch interval
set Fstep (Migrate_rate * dt / ds) ; baseline fib speed
= {M} patches/step
set IFspeed Fstep * Alpha_M
; IFib speed
set AFspeed Fstep * Beta_M
; AFib speed
set MFspeed Fstep * Gamma_M
; MFib speed
set SFspeed Fstep * Omega_M
; SFib speed
ask IFibs [set Fspeed IFspeed] ; re-sets IFib speed for post-scratch conditions
ask AFibs [set Fspeed AFspeed] ; re-sets AFib speed for post-scratch conditions
ask MFibs [set Fspeed MFspeed] ; re-sets MFib speed for post-scratch conditions
ask SFibs [set Fspeed SFspeed] ; re-sets SFib speed for post-scratch conditions
set t_div Prolife_rate / dt
; division rate mean = {P} hrs
set sd_div t_div / 3
; division rate st.dev. = {P} hrs
; averages pre+post-interval fission rates (ie cells fully adjust w next cell cycle)
ask turtles [ set fission ((fission + ((random-float 1) * t_div)) / 2) ]
set m_stim Stim_rate * dt
; 'stimulation' rate mean = {} stim/step
; averages pre+post-interval Zsense dist. to sim degrees of signalling overlap
ask turtles [ set Zsense ((Zsense + (random-normal 1 Stim_sense)) / 2) ]
set stim_Tm T_myo
; stim threshold(m) = lvl w 50% fib myo-trans. per hr
set stim_Ts T_sen
; stim threshold(s) = lvl w 50% fib senescence per hr
][]
; INITIATES WORLD AND SCRATCH AREA (CENTERED AROUND Y-AXIS)
if Experiment_Type = "Culture Cond." [ ; NO CHANGE W/ CULTURE CONDITIONS
set Scratch_width 0
set Scratch_center 0
set Scratch_edges 0
set Scratch patch-set nobody
set Pop_t0 count turtles
]
if Experiment_Type = "Scratch Healing" [ Scratch_Cells ] ; CREATE SCRATCH
if Experiment_Type = "Barrier Removal" [ Remove_Barrier ]; REMOVE BOUNDARY
calc_Vscores ; initiates void scores for plot initialization and model operation
Measure_Healed ; initiates/labels Healed and Unhealed Edge regions for reporters
set Edge_length_t0 Edge_length ; sets initial Unhealed Edge Length for reporters
reset-ticks
setup-plots
end

; sets tick counter to 0 and sets/updates all plots
; initiates plots (req. with "tick-advance" notation)
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;================================================================|
;; MODEL OPERATION
to go
react
age
divide
migrate

; Fibroblast stim (ticker) + hetero response (stoch. Xforms)
; Fibroblast replicative senesence (counter)
; Fibroblast proliferation (counter)
; Fibroblast migration (see below for mode descriptions)

calc_Vscores ; updates void scores for plot updates and model operation
Measure_Healed ; updates/labels Healed and UnHealed Edge regions for reporters
tick-advance dt ; moves model forward by 1 step = "dt" ticks
update-plots ; updates plots with each step (req. with "tick-advance" notation)
if ticks >= t_end [
; time limit for the model (slider, default = 24 hrs)
stop
repeat 2 [beep wait 1.6]] ; emits 2 beeps spaced 1.6s apart
end
;================================================================|
;; SHORTCUT TO PRECONDITION AGENT VARIABLES
to Precondition_Fibs
repeat time_SS [ ; Runs the "go" procedure from below for time_ss iterations
react
; Fibroblast stim (ticker) + hetero respone (stoch. Xforms)
age
; Fibroblast replicative senesence (counter)
divide
; Fibroblast proliferation (counter)
migrate
; Fibroblast migration (see below for mode descriptions)
calc_Vscores ; Calculates void scores
]
end
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;================================================================|
;; SHORTCUT TO SCRATCH CELL MONOLAYER
to Scratch_Cells
set Scratch_width floor((Vs_AR - world-height) / (2 * world-height))
; scratch width, excluding center and edges [rows/side] = 45 rows/side
set Scratch_center (world-height + ((2 * world-height) * Scratch_width))
; number of patches in filled rows, including center
= 4545 patches
set Scratch_edges Vs_AR - Scratch_center
; number of patches in the scratch's "ragged" edge
= 156 patches
set Scratch ( patch-set
patches with [ pxcor <= Scratch_width and pxcor >= (-1 * Scratch_width) ]
n-of Scratch_edges patches with [
pxcor = (Scratch_width + 1) or pxcor = (-1 * Scratch_width - 1)
])
ask Scratch [set pcolor grey]
; tags scratch patches
ask turtles-on patches with [
; clears cells from the scratch area & edges
(pxcor <= (Scratch_width + 2) and pxcor >= (-1 * Scratch_width - 2))
and (not member? self Apops) ][ die ]
ifelse Seed_IFibs_Only? [
; clears 'excess' dead cells
ask Apops [die] ][
let dead_pctIV14s round(.0805 * count turtles)
ifelse count Apops = dead_pctIV14s [][
if count Apops > dead_pctIV14s [
ask n-of (count Apops - dead_pctIV14s ) Apops [die] ]
if count Apops < dead_pctIV14s [
ask n-of (dead_pctIV14s - count Apops) turtles with [
not member? self Apops] [
ask patch-here [Fib_apoptose] die ]]
]
]
set Pop_t0 count turtles
; counts remaining cells for calculations
end
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;================================================================|
;; SHORTCUT TO REMOVE BARRIER (NOT A TRUE BARRIER REMOVAL)
to Remove_Barrier
set Scratch_width floor((Vs_AR - world-height) / (2 * world-height))
; scratch width, excluding center and edges [rows/side] = 45 rows/side
set Scratch_center (world-height + ((2 * world-height) * Scratch_width))
; number of patches in filled rows, including center
= 4545 patches
set Scratch_edges Vs_AR - Scratch_center
; number of patches in the scratch's "ragged" edge
= 156 patches
let Not_Scratch ( patch-set
patches with [ pxcor <= Scratch_width and pxcor >= (-1 * Scratch_width) ]
n-of Scratch_edges patches with [
pxcor = (Scratch_width + 1) or pxcor = (-1 * Scratch_width - 1)
])
set Scratch (patch-set patches with [not member? self Not_Scratch])
ask Scratch [ set pcolor grey ]
; tags non-boundary patches
ask turtles-on patches with [
; clears cells from the scratch area & edges
(member? self Scratch) and (not member? self Apops) ] [ die ]
ifelse Seed_IFibs_Only? [
; clears 'excess' dead cells
ask Apops [die] ][
let dead_pctIV14s round(.0805 * count turtles)
ifelse count Apops = dead_pctIV14s [][
if count Apops > dead_pctIV14s [
ask n-of (count Apops - dead_pctIV14s ) Apops [die] ]
if count Apops < dead_pctIV14s [
ask n-of (dead_pctIV14s - count Apops) turtles with [
not member? self Apops] [
ask patch-here [Fib_apoptose] die ]]
]
]
set Pop_t0 count turtles
; counts remaining cells for calculations
end
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;================================================================|
;; SHORTCUTS TO SET DEFAULT VARIABLES FOR EACH FIBROBLAST STATE
to train_IFib
; INACTIVATED FIBROBLASTS
set color 42
; ~60% shaded yellow
set size IFsize
set Fspeed IFspeed
set heading random 360
set life random-normal t_life sd_life
set fission random-normal t_div sd_div
end
to train_AFib
; ACTIVATED FIBROBLASTS
if Media = "FBM" [set color sky]
if Media = "FGM" [set color turquoise]
if Media = "CSC" [set color brown]
set size AFsize
set Fspeed AFspeed
set heading random 360
set life random-normal t_life sd_life
set fission random-normal t_div sd_div
set fission (fission + (t_div * (Beta_P - 1)))
end
to train_MFib
; MYO- FIBROBLASTS
if Media = "FBM" [set color 82.5] ; ~50% shaded cyan
if Media = "FGM" [set color 54] ; ~20% shaded green
if Media = "CSC" [set color orange]
set size MFsize
set Fspeed MFspeed
set heading random 360
set life random-normal t_life sd_life
set fission random-normal t_div sd_div
set fission (fission + (t_div * (Gamma_P - 1)))
end
to train_SFib
; SENESCENT FIBROBLASTS
if Media = "FBM" [set color 102.5] ; ~50% shaded blue
if Media = "FGM" [set color 72.5] ; ~50% shaded turquoise
if Media = "CSC" [set color red]
set size SFsize
set Fspeed SFspeed
set heading random 360
set life random-normal t_life sd_life
set fission random-normal t_div sd_div
set fission (fission + (t_div * (Omega_P - 1)))
end
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;================================================================|
;; SHORTCUTS TO TRANSITION BETWEEN FIBROBLAST STATES
to IFib_activate
; FIBROBLAST ACTIVATION
set breed AFibs
if Media = "FBM" [set color sky]
if Media = "FGM" [set color turquoise]
if Media = "CSC" [set color brown]
set size AFsize
set Fspeed AFspeed
set fission (fission + (t_div * (Beta_P - 1)))
end
to AFib_deactivate
; FIBROBLAST DEACTIVATION
set breed IFibs
set color 42
; ~60% shaded yellow
set size IFsize
set Fspeed IFspeed
set fission (fission - (t_div * (Beta_P - 1)))
end
to AFib_transmyo
; FIBROBLAST ACTIVATION
set breed MFibs
if Media = "FBM" [set color 82.5] ; ~50% shaded cyan
if Media = "FGM" [set color 54]
; ~20% shaded green
if Media = "CSC" [set color orange]
set size MFsize
set Fspeed MFspeed
set fission (fission + (t_div * (Gamma_P - 1)))
end
to Fib_senesce
; FIBROBLAST SENESCENCE
set breed SFibs
if Media = "FBM" [set color 102.5]
; ~50% shaded blue
if Media = "FGM" [set color 72.5]
; ~50% shaded turquoise
if Media = "CSC" [set color red]
set size SFsize
set Fspeed SFspeed
set fission (fission + (t_div * (Omega_P - Beta_P)))
end
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;================================================================|
;; SHORTCUT FOR STIMULATION & FIBROBLAST STATE CHANGES
to react
ask turtles [
; Stimulation counter increases each step
set stim (stim + (Zsense * m_stim))
]
ask turtles [
; Prob of fibroblast death
set P_die (stim / (20 * stim_max))
if breed = IFibs [ set P_die (P_die / Alpha_D) ] ; applies IFib apoptosis resist
if breed = AFibs [ set P_die (P_die / Beta_D) ] ; applies AFib apoptosis resist
if breed = MFibs [ set P_die (P_die / Gamma_D) ] ; applies MFib apoptosis resist
if breed = SFibs [ set P_die (P_die / Omega_D) ] ; applies SFib apoptosis resist
if random-float 1 <= P_die [
ask patch-here [Fib_apoptose]
; apoptotic body replaces fib
die
; and fib dies/disappears
]]
ask IFibs [
; Prob of fibroblast activation
set P_activate (stim / (2 * stim_Ta))
if random-float 1 <= P_activate [
IFib_activate
]]
ask AFibs [
; Prob of fibroblast deactivation
set P_deactivate (((2 * stim_T-a) - stim) / (2 * (stim_T-a)))
if random-float 1 <= P_deactivate [
AFib_deactivate
]]
ask AFibs [
; Prob of myofibroblast transition
set P_transmyo ((stim - stim_Ta) / (2 * (stim_Tm - stim_Ta)))
if random-float 1 <= P_transmyo [
AFib_transmyo
]]
ask turtles with [
(breed = AFibs) or (breed = MFibs) ][ ; Prob of fibroblast senescence
set P_senesce ((stim - stim_Ta) / (2 * (stim_Ts - stim_Ta)))
if random-float 1 <= P_senesce [
Fib_senesce
]]
end
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;================================================================|
;; SHORTCUT FOR PROLIFERATION COUNTER
to divide
ask turtles [ set fission fission - 1 ] ; division counter decreases by 1/tick
ask turtles [
if (fission <= 0)
and (any? neighbors with [ ( V2_score > 0.05 ) ; rep. avg V2score @ ~100%confl.
and (not any? other IFibs in-radius (IFsplit))
and (not any? other AFibs in-radius (AFsplit))
and (not any? other MFibs in-radius (MFsplit))
and (not any? SFibs in-radius (SFsplit)) ])
[
let parent_breed breed
let parent_stim stim
let parent_Zsense Zsense
let birthplace max-one-of neighbors [ V2_score ]
if parent_breed = IFibs [
hatch-IFibs 1 [
; spawns new IFib on old IFib
move-to birthplace
; moves new IFib to adjacent void patch
train_IFib
; applies default IFib values
set stim parent_stim
; stim is conserved between daughter cells
set Zsense parent_Zsense
]]
; stim sensitivity is conserved
if parent_breed = AFibs [
; AFibs divide into AFibs
hatch-AFibs 1 [
move-to birthplace
train_AFib
set stim parent_stim
set Zsense parent_Zsense
]]
; stim sensitivity is conserved
if parent_breed = MFibs [
; MFibs divide into MFibs
hatch-MFibs 1 [
move-to birthplace
train_MFib
set stim parent_stim
set Zsense parent_Zsense
]]
; stim sensitivity is conserved
if parent_breed = SFibs [
; SFibs dont divide
set stim parent_stim
; stim remains unchanged
set Zsense parent_Zsense
]
; stim sensitivity is conserved
set fission random-normal t_div sd_div ; resets counter of old agent
if breed = IFibs [set fission (fission + (t_div * (Alpha_P - 1)))]
if breed = AFibs [set fission (fission + (t_div * (Beta_P - 1)))]
if breed = MFibs [set fission (fission + (t_div * (Gamma_P - 1)))]
if breed = SFibs [set fission (fission + (t_div * (Omega_P - 1)))]
]
]
end
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;================================================================|
;; SHORTCUT TO SPROUT 'APOPTOTIC BODIES' FROM DEAD FIBROBLASTS
to Fib_apoptose
sprout-Apops 1 [
set color white
]
end

; DEAD CELLS

;================================================================|
;; SHORTCUT FOR REPLICATIVE SENESCENCE COUNTER
to age
ask turtles [ set life life - 1 ] ; Life counter decreases by 1 each tick.
ask turtles with [ not member? self Apops ] [
if life <= 0 [
; When life counter of living agent runs out,
Fib_senesce
; fibroblast agent becomes senescent
]
]
end
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;================================================================|
;; META-SHORTCUTS FOR FIB MIGRATION
to migrate
; Selects Migration method
ask turtles [
ifelse breed = SFibs [ move_rand ] [
if Nav_Method = "Random Walk"
[ ; Completely Random Walk
move_rand ]
if Nav_Method = "Void Triggered Random Walk" [ ; Void-triggered Random Walk
move_void_trig ]
if Nav_Method = "Void Directed"
[ ; To Random Voids
move_void_any ]
if Nav_Method = "Void1 Score - Directed" [ ; To Max V1-score (+sensitive)
move_V1score ]
if Nav_Method = "Void2 Score - Directed" [ ; To Max V2-score (+sensitive, range)
move_V2score ]
]
]
end
;------------------------------------------------------------------------------------|
;; SHORTCUT FOR FIB MOVEMENT-MODE: RANDOM WALK, ALWAYS
MOVING
to move_rand
set heading random-float 360
forward Fspeed
end
;------------------------------------------------------------------------------------|
;; SHORTCUT FOR FIB MOVEMENT-MODE: RANDOM WALK, TRIGGERED BY
VOID
to move_void_trig
set heading random-float 360
ifelse (any? neighbors with [(not any? other IFibs in-radius (IFmove))
and (not any? other AFibs in-radius (AFmove))
and (not any? other MFibs in-radius (MFmove))
and (not any? SFibs in-radius (SFmove)) ])[
forward Fspeed
]
[ ] ; moves randomly if void space is adjacent, else doesn't move
end
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;------------------------------------------------------------------------------------|
;; SHORTCUT FOR FIB MOVEMENT-MODE: DIRECTED TO RANDOM VOID,
TRIGGERED BY VOID
to move_void_any
ifelse (any? neighbors with [(not any? other IFibs in-radius (IFmove))
and (not any? other AFibs in-radius (AFmove))
and (not any? other MFibs in-radius (MFmove))
and (not any? SFibs in-radius (SFmove)) ])[
face one-of neighbors with [(not any? other IFibs in-radius (IFmove))
and (not any? other AFibs in-radius (AFmove))
and (not any? other MFibs in-radius (MFmove))
and (not any? SFibs in-radius (SFmove)) ]
set heading heading + random-normal 0 (45 / 3) ; biased to selected patch
forward Fspeed
] [ ] ; moves toward a void space if they are adjacent, else doesn't move
end

;------------------------------------------------------------------------------------|
;; SHORTCUT FOR FIB MOVEMENT-MODE: DIRECTED TO MAX VOID1-SCORE,
TRIGGERED BY V1SCORE
to move_V1score
ifelse (any? neighbors with [ V1_score > 0.05 ])[
face max-one-of neighbors [ V1_score ]
set heading heading + random-normal 0 (45 / 3) ; biased to selected patch
forward Fspeed
] [ ] ; moves toward a void space if they are adjacent, else doesn't move
end
;------------------------------------------------------------------------------------|
;; SHORTCUT FOR FIB MOVEMENT-MODE: DIRECTED TO MAX VOID2-SCORE,
TRIGGERED BY V2SCORE
to move_V2score
ifelse (any? neighbors with [ V2_score > 0.05 ])[
face max-one-of neighbors [ V2_score ]
set heading heading + random-normal 0 (45 / 3) ; biased to selected patch
forward Fspeed
] [ ] ; moves toward a void space if they are adjacent, else doesn't move
end
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;================================================================|
;; SHORTCUT TO CALCULATE VOID SCORES
to calc_Vscores
;ask patches [ ; sets V0score = normalized #neighbors(n=8) devoid of cell centers
; set V0_score (count neighbors with [ (not any? IFibs) and
; (not any? AFibs) and (not any? MFibs) and (not any? SFibs)]) / 8
; ] ; NOT SURE IF THIS METHOD WORKS OR CHANGES ANYTHING
ask patches [ ; sets V1score = normalized #neighbors(n=8) devoid of cells
set V1_score (count neighbors with [ (not any? IFibs in-radius IFsize) and
(not any? AFibs in-radius AFsize) and (not any? MFibs in-radius MFsize) and
(not any? SFibs in-radius SFsize)]) / 8
]
ask patches [ ; sets V2score = mean V1score of neighborhood
set V2_score mean [ V1_score ] of neighbors
]
end
;================================================================|
;; SHORTCUTS TO CALCULATE AND REPORT %HEALED AND POP.
PROPORTIONS AND PROBABILITIES
to Measure_Healed
if Measurement = "Edge_v1" [
set Healed ( patch-set patches with [
member? self Scratch and ( V1_score < 0.5 ) ] )
]
if Measurement = "Edge_v2" [
set Healed ( patch-set patches with [
member? self Scratch and ( V2_score < 0.5 ) ] )
]
if Measurement = "Edge_v1+2" [
set Healed ( patch-set patches with [
member? self Scratch and ( V1_score < 0.5 or V2_score < 0.5 ) ] )
]
set UnHealed ( patch-set patches with [
(member? self Scratch) and (not member? self Healed)
])
set UnHealed_edge ( patch-set patches with [
(member? self UnHealed) and (any? neighbors4 with [
not member? self UnHealed])
])
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if Show_Healed_Area? = true and Label_Leading_Edge? = true [
ask Scratch [ set pcolor grey ]
ask Healed [ set pcolor lime ]
ask UnHealed_edge [ set pcolor 6 ] ; tinted grey
]
if Show_Healed_Area? = true and Label_Leading_Edge? = false [
ask Scratch [ set pcolor grey ]
ask Healed [ set pcolor lime ]
]
if Show_Healed_Area? = false and Label_Leading_Edge? = true [
ask Scratch [ set pcolor grey ]
ask UnHealed_edge [ set pcolor 6 ] ; tinted grey
]
end
to-report %Cover
report 100 * ( Cell_AR / Rs_AR ) * Fibs_$
end
to-report %Healed
ifelse Measurement = "Cell_Areas" [ report %Cover ][
report 100 * (count patches with [member? self Healed]) / Vs_AR
]
end
to-report Edge_length
report ds * (sum [
count neighbors4 with [not member? self UnHealed]] of UnHealed_edge)
end
to-report Rel_Edge_length
report Edge_length / Edge_length_t0
end
to-report Divs_T
; number of divisions - overall
report count turtles - Pop_t0
end
to-report IFibs_T report count IFibs end
; inactive fib pop - overall
to-report AFibs_T report count AFibs end
; active fib pop - overall
to-report MFibs_T report count MFibs end
; myo- fib pop - overall
to-report SFibs_T report count SFibs end
; senescent fib pop - overall
to-report Dead_T report count Apops end
; dead pop overall
to-report Fibs_T
; total fib pop - overall
report (IFibs_T + AFibs_T + MFibs_T + SFibs_T)
end

115
to-report IFibs_$ report count IFibs-on Scratch end ; inactive fib pop - on scratch
to-report AFibs_$ report count AFibs-on Scratch end ; active fib pop - on scratch
to-report MFibs_$ report count MFibs-on Scratch end ; myo- fib pop - on scratch
to-report SFibs_$ report count SFibs-on Scratch end ; senescent fib pop - on scratch
to-report Dead_$ report count Apops-on Scratch end ; dead pop - on scratch
to-report Fibs_$
; total fib pop - on scratch
report (IFibs_$ + AFibs_$ + MFibs_$ + SFibs_$)
end
to-report IvTFibs_$vT ; relative ratio of IFibs in the scratch vs overall
let IvT_$vT 0
ifelse (Fibs_$ = 0) or (Fibs_T = 0) or (IFibs_T = 0) [ ] [
set IvT_$vT (IFibs_$ / Fibs_$) / (IFibs_T / Fibs_T)
]
report IvT_$vT
end
to-report AvTFibs_$vT ; relative ratio of AFibs in the scratch vs overall
let AvT_$vT 0
ifelse (Fibs_$ = 0) or (Fibs_T = 0) or (AFibs_T = 0) [ ] [
set AvT_$vT (AFibs_$ / Fibs_$) / (AFibs_T / Fibs_T)
]
report AvT_$vT
end
to-report MvTFibs_$vT ; relative ratio of MFibs in the scratch vs overall
let MvT_$vT 0
ifelse (Fibs_$ = 0) or (Fibs_T = 0) or (MFibs_T = 0) [ ] [
set MvT_$vT (MFibs_$ / Fibs_$) / (MFibs_T / Fibs_T)
]
report MvT_$vT
end
to-report SvTFibs_$vT ; relative ratio of SFibs in the scratch vs overall
let SvT_$vT 0
ifelse (Fibs_$ = 0) or (Fibs_T = 0) or (SFibs_T = 0) [ ] [
set SvT_$vT (SFibs_$ / Fibs_$) / (SFibs_T / Fibs_T)
]
report SvT_$vT
end
to-report Dead_$vT
; relative ratio of Death in the scratch vs overall
let DvT_$vT 0
ifelse (Fibs_$ = 0) or (Fibs_T = 0) or (Dead_T = 0) [ ] [
set DvT_$vT (Dead_$ / (count turtles-on Scratch)) / (Dead_T / count turtles)
]
report DvT_$vT
end
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to-report MeanP_activate ; mean probability for inactive fibroblast activation
let mean_stim 0
ifelse any? IFibs [
set mean_stim (Mean [stim] of turtles with [ member? self IFibs ])
][
set mean_stim (2 * stim_Ta)
; if no IFibs, P_act = 1
]
let P_act mean_stim / (2 * stim_Ta)
if P_act < 0 [ set P_act 0 ]
if P_act > 1 [ set P_act 1 ]
report P_act
end
to-report MeanP_deactivate ; mean probability for activated fibroblast inactivation
let mean_stim 0
ifelse any? AFibs [
set mean_stim (Mean [stim] of turtles with [ member? self AFibs ])
][]
let P_deact (((2 * stim_T-a) - mean_stim) / (2 * stim_T-a))
if P_deact < 0 [ set P_deact 0 ]
if P_deact > 1 [ set P_deact 1 ]
report P_deact
end
to-report MeanP_transmyo ; mean probability for senescence of active fibroblasts
let mean_stim 0
ifelse any? AFibs [
set mean_stim (Mean [stim] of turtles with [ member? self AFibs ])
][]
let P_myo ((mean_stim - stim_Ta) / (2 * (stim_Tm - stim_Ta)))
if P_myo < 0 [ set P_myo 0 ]
if P_myo > 1 [ set P_myo 1 ]
report P_myo
end
to-report MeanP_senesce ; mean probability for senescence of active and myo-fibs
let mean_stim 0
ifelse (any? AFibs) or (any? MFibs) [
set mean_stim (Mean [stim] of turtles with [(breed = AFibs) or (breed = MFibs)])
][]
let P_sen ((mean_stim - stim_Ta) / (2 * (stim_Ts - stim_Ta)))
if P_sen < 0 [ set P_sen 0 ]
if P_sen > 1 [ set P_sen 1 ]
report P_sen
end
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to-report MeanP_die
; mean probability of fibroblast death due to stimulation
let mean_stim (Mean [stim] of turtles with [not member? self Apops])
report mean_stim / (2 * stim_max)
end
to-report Mean_Pact-Pdeact ; calcs mean ratio of activation / inativation rates
let M_AvDa 1
ifelse MeanP_deactivate = 0 [ ] [ set M_AvDa ( MeanP_activate / MeanP_deactivate ) ]
report M_AvDa
end
to-report Mean_Pmyo-Pact ; calcs mean ratio of myofibroblast / activation rates
let M_MvA 1
ifelse MeanP_activate = 0 [ ] [ set M_MvA ( MeanP_transmyo / MeanP_activate ) ]
report M_MvA
end
to-report Mean_Psen-Pmyo ; calcs mean ratio of senescence / myofibroblast rates
let M_SvM 1
ifelse MeanP_transmyo = 0 [ ][ set M_SvM ( MeanP_senesce / MeanP_transmyo ) ]
report M_SvM
end
to-report Mean_Psen-Pdie ; calcs mean ratio of senescence / death rates
let M_SvD 1
ifelse MeanP_die = 0 [ ][ set M_SvD ( MeanP_senesce / MeanP_die ) ]
report M_SvD
end
to-report Mean_Pdie-Pmyo ; calcs mean ratio of death / myofibroblast rates
let M_MvD 1
ifelse MeanP_transmyo = 0 [ ][ set M_MvD ( MeanP_die / MeanP_transmyo ) ]
report M_MvD
end
to-report Mean_Pact-Pdie ; calcs mean ratio of activation / death rates
let M_AvD 1
ifelse MeanP_die = 0 [ ][ set M_AvD ( MeanP_activate / MeanP_die ) ]
report M_AvD
end
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; Calculates Mean Void2 Scores by Patch Region's |x-coord|
to-report V2mean_0-8
report mean [V2_score] of patches with [ (pxcor >= -8) and (pxcor <= 8) ]
end
to-report V2mean_9-16
report mean [V2_score] of patches with [
((pxcor >= -16) and (pxcor <= -9))
or ((pxcor >= 9) and (pxcor <= 16))
]
end
to-report V2mean_17-24
report mean [V2_score] of patches with [
((pxcor >= -24) and (pxcor <= -17))
or ((pxcor >= 17) and (pxcor <= 24))
]
end
to-report V2mean_25-33
report mean [V2_score] of patches with [
((pxcor >= -33) and (pxcor <= -25))
or ((pxcor >= 25) and (pxcor <= 33))
]
end
to-report V2mean_34-42
report mean [V2_score] of patches with [
((pxcor >= -42) and (pxcor <= -34))
or ((pxcor >= 34) and (pxcor <= 42))
]
end
to-report V2mean_43-50
report mean [V2_score] of patches with [
((pxcor >= -50) and (pxcor <= -43))
or ((pxcor >= 43) and (pxcor <= 50))
]
end
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;================================================================|
;; SHORTCUT FOR CODE USED TO SETUP IN VITRO %HEALED RANGES FOR
MODEL COMPARISONS
to plot_IV_%Healed
let x-vals (list 0 4 8 12 16 20 24)
; Scratch Assay timepoints
let y-means (list 0.00 0.00 0.00 0.00 0.00 0.00 0.00)
let y-sds (list 0.00 0.00 0.00 0.00 0.00 0.00 0.00)
if Experiment_Type = "Scratch Healing" [
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 0.00 17.40 45.29 56.79 63.88 76.65 86.64)
set y-sds (list 0.00 5.20 3.37 7.02 6.48 10.23 5.93)
]
if Media = "FBM" [
set y-means (list 0.00 9.58 23.01 34.88 45.46 56.34 64.16)
set y-sds (list 0.00 3.48 6.84 7.99 6.41 10.46 10.62)
]
if Media = "CSC" [
set y-means (list 0.00 6.00 14.28 23.49 34.93 45.38 52.17)
set y-sds (list 0.00 0.86 9.32 9.70 10.59 9.96 10.16)
]
]
if Cell_Line = "DHLF" [
if Media = "FGM" [
]
if Media = "FBM" [
set y-means (list 0.00 12.01 19.96 21.13 24.51 28.26 39.30)
set y-sds (list 0.00 8.96 14.90 10.68 15.94 18.87 20.47)
]
if Media = "CSC" [
set y-means (list 0.00 5.30 15.52 13.53 15.56 21.16 28.83)
set y-sds (list 0.00 3.75 10.97 8.40 5.42 7.22 12.23)
]
]
let index 0
while [ index < length x-vals ] [
plotxy (item index x-vals) ((item index y-means) + (2 * (item index y-sds)))
plotxy (item index x-vals) ((item index y-means) - (2 * (item index y-sds)))
set index (index + 1)
]
]
end
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;================================================================|
;; SHORTCUT FOR CODE USED TO SETUP IN VITRO MTT RANGES FOR MODEL
COMPARISONS
to plot_IV_MTT
let x-vals (list 0 2 12 24)
; MTT/CCK8 timepoints
let y-means (list 0.00 0.00 0.00 0.00 0.00 )
let y-sds (list 0.00 0.00 0.00 0.00 0.00 )
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means map [( (? + 1) * Pop_t0 )] (list 1.000 1.182 0.944 1.095)
set y-sds map [( ? * Pop_t0 )] (list 0.181 0.107 0.057 0.080)
]
if Media = "FBM" [
set y-means map [( (? + 1) * Pop_t0 )] (list 1.000 1.119 0.977 0.968)
set y-sds map [( ? * Pop_t0 )] (list 0.181 0.132 0.127 0.120)
]
if Media = "CSC" [
set y-means map [( (? + 1) * Pop_t0 )] (list 1.000 1.047 1.018 0.765)
set y-sds map [( ? * Pop_t0 )] (list 0.181 0.137 0.098 0.125)
]
]
let index 0
while [ index < length x-vals ] [
plotxy (item index x-vals) ((item index y-means) + (2 * (item index y-sds)) - Pop_t0)
plotxy (item index x-vals) ((item index y-means) - (2 * (item index y-sds)) - Pop_t0)
set index (index + 1)
]
end
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;================================================================|
;; SHORTCUT FOR CODE USED TO SETUP IN VITRO Totlnorm RANGES FOR
MODEL COMPARISONS
to plot_IV_Totlnorm
let x-vals (list 0.00 0.00 0.00)
let y-means (list 0.00 0.00 0.00 )
let y-sds (list 0.00 0.00 0.00 )
if Experiment_Type = "Culture Cond." [
set x-vals (list 0 8)
; Staining timepoints (pre-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means map [( (? + 1) * Pop_t0 )] (list 1.000 1.313)
set y-sds map [( ? * Pop_t0 )] (list 0.278 0.316)
]
]
]
if Experiment_Type = "Scratch Healing" [
set x-vals (list 0 12 24)
; Staining timepoints (post-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means map [( (? + 1) * Pop_t0 )] (list 1.000 1.163 1.534)
set y-sds map [( ? * Pop_t0 )] (list 0.487 0.376 0.335)
]
if Media = "FBM" [
set y-means map [( (? + 1) * Pop_t0 )] (list 1.000 1.043 1.130)
set y-sds map [( ? * Pop_t0 )] (list 0.487 0.497 0.524)
]
if Media = "CSC" [
set y-means map [( (? + 1) * Pop_t0 )] (list 1.000 0.948 1.114)
set y-sds map [( ? * Pop_t0 )] (list 0.487 0.300 0.273)
]
]
]
let index 0
while [ index < length x-vals ] [
plotxy (item index x-vals) ((item index y-means) + (2 * (item index y-sds)) - Pop_t0)
plotxy (item index x-vals) ((item index y-means) - (2 * (item index y-sds)) - Pop_t0)
set index (index + 1)
]
end
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;================================================================|
;; SHORTCUT FOR CODE USED TO SETUP IN VITRO Totl RANGES FOR MODEL
COMPARISONS
to plot_IV_Totl
let x-vals (list 0.00 0.00 0.00)
let y-means (list 0.00 0.00 0.00 )
let y-sds (list 0.00 0.00 0.00 )
if Experiment_Type = "Culture Cond." [
set x-vals (list 0 8)
; Staining timepoints (pre-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 409.4 537.8)
set y-sds (list 113.9 129.4)
]
]
]
if Experiment_Type = "Scratch Healing" [
set x-vals (list 0 12 24)
; Staining timepoints (post-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 415.9 483.8 638.0)
set y-sds (list 202.7 156.2 139.3)
]
if Media = "FBM" [
set y-means (list 415.9 433.9 470.2)
set y-sds (list 202.7 206.7 217.8)
]
if Media = "CSC" [
set y-means (list 415.9 394.4 463.3)
set y-sds (list 202.7 124.6 113.7)
]
]
]
let index 0
while [ index < length x-vals ] [
plotxy (item index x-vals) ((item index y-means) + (2 * (item index y-sds)))
plotxy (item index x-vals) ((item index y-means) - (2 * (item index y-sds)))
set index (index + 1)
]
end

123
;================================================================|
;; SHORTCUT FOR CODE USED TO SETUP IN VITRO % Dead RANGES FOR
MODEL COMPARISONS
to plot_IV_dead
let x-vals (list 0.00 0.00 0.00)
let y-means (list 0.00 0.00 0.00 )
let y-sds (list 0.00 0.00 0.00 )
if Experiment_Type = "Culture Cond." [
set x-vals (list 0 8)
; Staining timepoints (pre-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 1.48 3.04)
set y-sds (list 0.56 0.54)
]
]
]
if Experiment_Type = "Scratch Healing" [
set x-vals (list 0 12 24)
; Staining timepoints (post-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 8.05 2.72 1.63)
set y-sds (list 1.85 0.50 0.63)
]
if Media = "FBM" [
set y-means (list 8.05 4.04 1.82)
set y-sds (list 1.85 0.57 0.21)
]
if Media = "CSC" [
set y-means (list 8.05 3.69 2.11)
set y-sds (list 1.85 1.99 0.71)
]
]
]
let index 0
while [ index < length x-vals ] [
plotxy (item index x-vals) ((item index y-means) + (2 * (item index y-sds)))
plotxy (item index x-vals) ((item index y-means) - (2 * (item index y-sds)))
set index (index + 1)
]
end
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;================================================================|
;; SHORTCUT FOR CODE USED TO SETUP IN VITRO % SA-B-Gal RANGES FOR
MODEL COMPARISONS
to plot_IV_bgal
let x-vals (list 0.00 0.00)
let y-means (list 0.00 0.00)
let y-sds (list 0.00 0.00)
if Experiment_Type = "Culture Cond." [
set x-vals (list 0 8)
; Staining timepoints (pre-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 11.91 17.42)
set y-sds (list 3.37 1.55)
]
]
]
if Experiment_Type = "Scratch Healing" [
set x-vals (list 0 12 24)
; Staining timepoints (post-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 16.72 48.29 20.43)
set y-sds (list 5.51 7.72 1.72)
]
if Media = "FBM" [
set y-means (list 16.72 31.71 13.64)
set y-sds (list 5.51 2.22 3.17)
]
if Media = "CSC" [
set y-means (list 16.72 23.12 21.65)
set y-sds (list 5.51 11.84 2.51)
]
]
]
let index 0
while [ index < length x-vals ] [
plotxy (item index x-vals) ((item index y-means) + (2 * (item index y-sds)))
plotxy (item index x-vals) ((item index y-means) - (2 * (item index y-sds)))
set index (index + 1)
]
end
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;================================================================|
;; SHORTCUT FOR CODE USED TO SETUP IN VITRO % aSMA RANGES FOR
MODEL COMPARISONS
to plot_IV_asma
let x-vals (list 0.00 0.00)
let y-means (list 0.00 0.00)
let y-sds (list 0.00 0.00)
if Experiment_Type = "Culture Cond." [
set x-vals (list 0 8)
; Staining timepoints (pre-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 4.35 13.49)
set y-sds (list 1.45 0.39)
]
]
]
if Experiment_Type = "Scratch Healing" [
set x-vals (list 0 12 24)
; Staining timepoints (post-scratch)
if Cell_Line = "NHLF" [
if Media = "FGM" [
set y-means (list 20.97 27.83 23.21)
set y-sds (list 3.40 3.74 4.20)
]
if Media = "FBM" [
set y-means (list 20.97 17.38 10.90)
set y-sds (list 3.40 0.37 1.38)
]
if Media = "CSC" [
set y-means (list 20.97 58.91 14.48)
set y-sds (list 3.40 22.87 4.41)
]
]
]
let index 0
while [ index < length x-vals ] [
plotxy (item index x-vals) ((item index y-means) + (2 * (item index y-sds)))
plotxy (item index x-vals) ((item index y-means) - (2 * (item index y-sds)))
set index (index + 1)
]
end
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;================================================================|
;; SHORTCUT TO MAKE & EXPORT A MOVIE OF THE VIEW OR INTERFACE
to make_movie
movie-cancel
; cancels movie if still filming
setup
let movie_name "Model_0.3.7_"
if movie_type = "World View" [
; films movie of world view
set movie_name (word movie_name "View_" Cell_Line"_" Media"_" Movie_Title
".mov")
movie-start movie_name
movie-set-frame-rate (1 / dt)
; sets the frame rate 1 tick/sec
movie-grab-view
; shows the initial state
repeat (1 + (t_end / dt)) [
go
movie-grab-view
; shows state with each step
]
]
if movie_type = "Interface" [
; films movie of model interface
set movie_name (word movie_name "UI_" Cell_Line"_" Media"_" Movie_Title ".mov")
movie-start movie_name
movie-set-frame-rate (1 / dt)
movie-grab-interface
repeat (1 + (t_end / dt)) [
go
movie-grab-interface
]
]
print (word movie_name " has completed at "
date-and-time " with " t_end " hours simulated over " movie-status)
; prints movie
info upon completion
repeat 3 [beep wait 1]
; emits 3 beeps spaced 1s apart
movie-close
end
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APPENDIX B
Variable
Value
Unit
Description
tick
1
hour
Model counter
world-height
101
patches
Model world height
Iheight
1677
µm
In vitro image height*
dt
1/3
tick/step
Time resolution (= 20min/step)
ds
16.6040
um/patch
Spatial resolution
2
Rs_AR
1296089.39 µm
In vitro scratch area*
N_diam
30.0
µm
NHLF diameter mean 61
Time_seed-scratch 6
hours
Seed-Scratch time interval*
Pop_Ss
1172
agents
Seeded population*
MPop_S
0.0435
ratio
Seeded MFibs*
SPop_S
0.1191
ratio
Seeded SFibs*
DPop_S
0.0148
ratio
Seeded DFibs*
IPop_S
0
ratio
Seeded IFibs 49
APop_S
remaining
ratio
Seeded AFibs 49*
Alpha_Z
0.75
ratio
IFib size coefficient
Alpha_M
0
ratio
IFib speed coefficient
Alpha_P
1
ratio
IFib division period coefficient
Alpha_D
1
ratio
IFib death resistance coefficient
Beta_Z
1
ratio (ref.) AFib size coefficient
Beta_M
1
ratio (ref.) AFib speed coefficient
Beta_P
1
ratio (ref.) AFib division period coefficient
Beta_D
1
ratio (ref.) AFib death resistance coefficient
Gamma_Z
1.4
ratio
MFib size coefficient 61
Gamma_M
0.625
ratio
MFib speed coefficient 61
Gamma_P
1.4
ratio
MFib division period coefficient 61
Gamma_D
1.4
ratio
MFib death resistance coefficient
Omega_Z
2
ratio
SFib size coefficient 40
Omega_M
0.75
ratio
SFib speed coefficient 124
Omega_P
1000
ratio
SFib division period coefficient 40
Omega_D
1000
ratio
SFib death resistance coefficient 40
Model constants controlling temporal-spatial resolution and initial conditions for scratch
closure simulations. * indicates values determined from in vitro experiments with NHLF.
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Parameter
Value
Unit
Description
Migrate_rate
$
µm/hour
AFib migration rate
Prolife_rate
$
hour/split AFib proliferation rate
T_myo
$
stim
Myofibroblast stimulation threshold
T_sen
$
stim
Senescence stimulation threshold
Stim_rate
$
stim/hour Environmental stimuli magnitude
Stim_sense
$
ratio
Stimuli sensitivity distribution
Model parameters controlling agent characteristics and responses to stimulation during
scratch closure simulations. $ indicates parameters calibrated to in vitro experiments.

UI Setting

Value
NHLF
DHLF
FGM
FBM
CSC
Culture Cond.

Description
Counter-plot NHLF in vitro data ranges
Cell_Line
Counter-plot DHLF in vitro data ranges
Green-gradient agents
Media
Blue-gradient agents
Red-gradient agents
No voided region; no gradients.
Whole region seeded with N agents;
Scratch Healing
central region denuded of ~N/2 agents at
Experiment_Type
time T to instigate invasive behaviors
Central region is filled with ~N/2 agents;
Barrier Removal
allowed to invade at time T
In Vitro
Seed same number of agents as in vitro
Seed_Density
Max Confluency Seed max number of agents sans overlap
Seed_IFibs_Only?
On/Off
Toggles “all inactive” or “in vitro ratios”
Precondition?
On/Off
Toggles precondition interval
Show_Healed_Area?
On/Off
Toggles green-labeled Healed region
Label_Leading_Edge?
On/Off
Toggles grey-labeled Unhealed Edge
User interface settings that control the model display and additional functionalities.
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APPENDIX C
Group
NHLF
FGM

NHLF
FBM

Parameter
Total Population
%Dead
Modulation
12 HR
24 HR
12 HR
24 HR
M
+
-5.9
-4.3
3.4
2.3
-10.9
-10.0
4.9
4.6
P
+
-6.3
-5.8
5.4
7.0
-7.2
-5.4
3.9
3.0
LM
+
-10.5
-9.1
2.4
1.8
-6.7
-6.1
4.3
3.7
LS
+
-7.4
-5.2
2.3
-0.2
-10.5
-10.0
3.1
3.2
AM
+
-9.5
-8.7
3.1
3.8
-4.2
-2.5
2.5
2.6
AS
+
-12.5
-11.1
1.8
0.4
-4.8
-3.9
2.9
3.9
M
+
-1.5
-4.0
0.2
1.6
1.2
-2.7
1.9
5.5
P
+
-2.2
-4.7
1.8
3.0
-2.1
-5.0
-0.4
2.5
LM
+
-5.4
-7.6
1.4
3.7
-1.4
-5.0
1.2
4.7
LS
+
-1.0
-3.3
0.9
3.4
-4.3
-7.8
0.4
3.5
AM
+
-4.0
-7.6
2.0
5.4
-1.4
-3.4
0.8
2.0
AS
+
0.9
-1.5
3.0
5.5
-2.9
-5.4
1.1
3.6
(Table continued on next page)
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Group

Parameter
Total Population
%Dead
Modulation
12 HR
24 HR
12 HR
24 HR
NHLF
M
+
-3.9
-3.1
1.2
2.1
CSM
0.8
0.4
2.4
2.5
P
+
-3.8
-4.1
1.7
3.0
-4.4
-3.8
0.3
-1.2
LM
+
-1.5
-1.5
1.2
0.4
-0.6
-0.8
0.0
2.4
LS
+
-0.6
0.3
1.8
3.1
-0.9
-1.6
2.1
3.1
AM
+
-5.3
-5.2
1.8
0.6
-5.1
-4.9
1.3
1.4
AS
+
1.2
0.8
1.8
5.8
-4.0
-4.6
0.7
3.1
DHLF
M
+
-1.7
-2.0
-0.6
0.8
0.5
0.7
2.0
3.8
P
+
-5.6
-5.9
1.3
3.3
0.2
0.4
-0.5
-1.3
LM
+
-4.7
-5.0
0.9
3.2
-4.6
-5.1
0.7
2.2
LS
+
4.7
5.1
-0.6
0.3
-1.3
-1.7
-0.9
0.7
AM
+
-1.1
-1.3
2.3
6.4
-6.1
-5.1
0.6
0.2
AS
+
0.1
0.2
-0.8
0.1
0.8
0.8
1.2
1.6
Heat-map of each calibrated parameter-set’s sensitivity to parameter changes; expressed as
the percentage difference from the calibrated parameter-set’s mean output when each
parameter is independently modulated by ± 10%. Model outputs are shown for the total
population and percentage of dead cells after 12 or 24 hours. Parameter-set mean outputs
were calculated from 10 simulations with the same conditions. A blue-red gradient was
applied across all outputs and parameter modulations within each group.
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